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Summary
Transcription is a tightly controlled process that involves the recruitment and prost-translational
modification of DNA-associated protein complexes, which can be mapped to the genome using
high-throughput experimental assays. An accurate annotation of genomic elements such as tran-
scription units or cis-regulatory elements such as promoters or enhancers is crucial for the use and
interpretation of data generated by these assays. Thus, integrative genomic data analysis of high-
throughput assays with hidden Markov models (HMMs) has become a popular tool for genome
annotation. However, current algorithms are limited by unrealistic data distribution assumptions
and variance models. Moreover, they are not able to assign forward or reverse direction to states
or properly integrate strand-specific (e.g., RNA expression) with non-strand-specific (e.g., ChIP)
data, which is essential to characterize directed processes such as transcription.
In this thesis new HMM-based methods are proposed to overcome these limitations. These in-
clude (i) bidirectional HMMs (bdHMMs) which integrate strand-specific with non-strand-specific
data to infer directed genomic states de novo and (ii) GenoSTAN (Genomic STate ANnotation),
a HMM using discrete probability distributions to model count data, for genome annotation from
Next-Generation-Sequencing data. Both approaches are made available in the R/Bioconductor
package STAN (STate ANnotation) which provides an efficient implementation that can be run
on large genomes such as human.
STAN is used to derive new and improved annotations of transcription in yeast and human and
to generate a map of promoters and enhancers in 127 human cell types and tissues.
Integration of transcription factor binding and RNA expression data in yeast recovers the major-
ity of transcribed loci, reveals gene-specific variations in the yeast transcription cycle, identifies
32 new transcribed loci, a regulated initiation-elongation transition, the absence of elongation
factors Ctk1 and Paf1 from a class of genes, a distinct transcription mechanism for highly ex-
pressed genes and novel DNA sequence motifs associated with transcription termination.
Moreover, promoters and enhancers are predicted in 127 human cell types and tissues are mapped
by integrating sequencing data from the ENCODE and Roadmap Epigenomics projects, today’s
largest compendium of chromatin assays. Promoters and enhancers are identified with con-
sistently higher accuracy and show significantly higher enrichment of complex trait-associated
genetic variants than current annotations. Investigation of binding of 101 transcription factors
in human K562 cells reveals common and distinctive TF binding properties of enhancers and
promoters.
Application of STAN to transient transcriptome sequencing (TT-Seq) data in human K562 cells
recovers stable mRNAs, long intergenic non-coding RNAs, and additionally maps over 10,000
transient RNAs, including enhancer RNAs, antisense RNAs, and promoter-associated RNAs.
Further analyses reveal that transient RNAs such as enhancer RNAs are short and lack U1 mo-
tifs and secondary structure.
Taken together, the annotations inferred in this thesis gave new insights into transcription and
its regulation and will be an important resource for future research in genomics. STAN is a valu-
able tool to create such annotations also in other organisms and as more data becomes available
improve the existing ones.
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Part I
Introduction
Transcription is a fundamental process of life and crucial for the development and function of
living organisms. Transcription of a DNA template into messenger RNA (mRNA) is the first step
of the central dogma of molecular biology [1]. mRNA synthesis is catalyzed in the cell’s nucleus by
RNA Polymerase II (Pol II), exported into the cytoplasm and translated into proteins by a multi-
prtoein complex called the ribosome [2]. Besides mRNA, Pol II produces several other species of
non-coding RNAs, including small nuclear RNA (snRNA), small nucleolar RNA (snoRNA) and
other stable and instable RNAs such as cryptic unstable transcripts (CUTs), stable unannotated
transcripts (SUTs) or enhancer RNAs (eRNA) [3, 4, 5]. There exist two other Polymerases in
eurkaryotes, RNA Polymeras I (Pol I) and III (Pol III) [6]. Pol I transcribes the ribosomal RNA
(rRNA), which is part of the ribosome and neccessary for translation of mRNA into protein.
Pol III transcribed transfer RNA (tRNA), which carry amino acids to the ribosome for protein
synthesis. It is of great importance to understand the underlying mechanisms of transcription
and its regulation since transcription defects have been shown to be implicated in a variety of
diseases [7, 8].
.
1 Transcription regulation by cis-regulatory elements
Whether a gene is transcribed or not is controlled by cis-regulatory elements in the DNA. In
yeast, transcription regulation is mostly carried out by two cis-regulatory elements: promoters,
upstream activating sequences (UASs) and silencer sequences (Figure 1) [9]. Each of these el-
ements harbours binding sites of transcription factors (TFs) which control gene transcription
upon binding. Promoters are the most fundamental cis-regulatory elements required for gene
transcription. These elements are regions of DNA that initiate transcription of a particular gene.
They are located near the transcription start sites of genes, on the same strand and upstream.
The UAS and silencer sequences are usually located within several hundred base pairs from the
promoter.
In metazoans, the cis-regulatory architecture is more complex (Figure 1). Additionally to pro-
moters, there are enhancer regions, which were originally defined as DNA elements that can
increase expression of a gene over a long distance in an orientaton-independent fashion rela-
tive to the gene [10]. In mammals these elements can be located megabases from their target
gene [11]. However, experimental results showing that yeast UASs act as enhancers when ex-
pressed in human HeLa cells indicate that UASs and enhancers are functioanlly analogue [12].
The recent discovery of pervasive transcription at enhancers [3, 13] challenged the original en-
hancer definition and there is an ongoing debate about the differences between enhancers and
promoters [14]. Metazoan silencers suppress transcription and can be located within kilobases
upstream or downstream of their target gene [9].
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Figure 1: Comparison of a simple eukaryotic promoter and diversified metazoan regulatory modules
adopted from [9]. (A) Simple eukaryotic cis-regulatory elements include promoters, upstream activating
sequences and silencer elements, which are loctated within several hundred base pairs upstream of the
transcription start site (TSS). Cis-regulatory elements harbour binding sites of transcription factors which
control gene transcription. For instance, the TATA-binding protein (TBP) binds to the TATA-box in the
promoter during formation of the pre-initiation complex (PIC). (B) The regulatory architecture is more
complex in metazoans. Enhancer and silencer elements can be located within megabases upstream or
downstream of the TSS.
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1.1 Transcription regulation by UASs and enhancers
The first step in transcription regulation is the sequence-specific binding of transcription factors
to UASs or metazoan enhancers or silencers to control gene activation or repression [9, 15]. In
contrast to lower eukaryotes, transcription of metazoan genes is usually controlled by multiple
enhancer regions, each of which contributes to the expression profile of the gene [9]. Moreover,
inactive enhancers are known to be bound by pioneer factors such as FOXA1 during development
to drive cell-type specification and therefore mediate transcription in a tissue- or cell-type-specific
manner [16,17].
1.2 The pre-initiation complex assembles at the promoter
A specific class of TFs - the general transcription factors (GTFs) - assembles at the promoter into
the pre-initiation complex (PIC) before transcription is initiated (Figure 2). In vitro experiments
have shown that six general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and
TFIIH) assemble into the PIC [18]. According to this model, TFIID is the first protein to bind
the promoter. One of its subunits, the TATA-binding protein (TBP) - recognizes and binds the
TATA-box. This is followed by binding of TFIIB, which stabilizes TFIID binding to the promoter
and aids in the recruitment of the TFIIF-Pol II complex [18, 19]. PIC assembly is completed by
binding of TFIIE and TFIIH, which are required for transcription initiation. However, in vivo PIC
assembly might be more variable with more transcription factors involved since the heterogeneity
of promoters suggests different paths to promoter recognition [19].
1.3 The mediator complex
The mediator complex is a highly conserved protein complex consisting of 21 subunits in yeast
and 26 subunits in mammals [20]. It is involved in global transcription control by associating
with the sequence-specific TFs bound to the UAS or enhancer, Polymerase and the promoter [21].
To this end, the mediator complex acts as a bridge between enhancer and promoter regions to
communicate regulatory signals by protein-protein-interactions, but the exact mechanisms remain
to be elucidated.
2 The transcription cycle
Transcription folows a series of steps, the transcription cycle. Each step in the transcription cycle
is tightly controlled and requires specific proteins or protein modifications. The following sections
focus on studies and transcription factors in S. cerevisiae. If not noted otherwise, the mentioned
TFs are yeast TFs. A list of all factors analyzed in this work and their role in the transcription
cycle is shown in Table 1.
2.1 Initiation and promoter escape
Initiation starts with the formation of the open complex [15], where double-stranded DNA is
inserted into the jaw and downstream cleft of Pol II, which is assisted by TFIIB [37]. Stimulated
by TFIIE, the DNA-Helicase TFIIH separates both strands, which is followed by the insertion
of the single-stranded DNA into the active site of Pol II [37]. Then Pol II scans the downstream
nucleotides for a TSS with the help of the TFIIB-reader domain and initiates transcription,
leading to the ’initially transcribing complex’ [37,38]. This inital phase of transcription is abortive.
3
factor function
Nucleosome Most basic structural unit of chromatin [2]
Pcf11 3´-RNA processing factor interacts with phosphorylated serine 2
at the CTD [22,23]
Rna15 Component of the cleavage and polyadenylation factor I [22, 23]
Nrd1 Binds phosphorylated serine 5 and a tetramer in the RNA to mediate 3’-end
formation of some mRNAs, snRNAs, snoRNAs, and CUTs [24,25,26]
Ctk1 Essential protein that phosphorylates serine 2 at the CTD [27]
Paf1 Subunit of the Paf complex which recruits histone modifiers [28]
Spt16 Part of the FACT complex which reorganizes nucleosomes to facilitate
access to DNA during elongation [29]
Bur1 Non-essential protein that can phosphorylate serine 2 at the CTD [30]
Spt5 Regulation of transcription elongation and involved in
capping by binding guanylyltransferases [31,32]
Spn1 Involved in transcription elongation. Binding correlates with
serine 2 phosphorylation at the CTD [31,33]
Cbp20 Part of the cap-binding complex that binds co-transcriptionally to the 5’ cap
of pre-mRNAs [31]
Cet1 RNA 5’-triphosphatase involved in mRNA 5’ capping [31]
Abd1 Catalyzes the transfer of a methyl group to the 5’ end of capped mRNA [31]
TFIIB General transcription factor which is part of the pre-initiation complex and
required for transcription initiation [18]
Kin28 Subunit of the general transcription factor TFIIH, which phosphorylates
serine 5 at the CTD [34]
Rpb3 Subunit of RNA polymerase II [35]
Ser2P Recruits Spt6 and RNA 3’-processing and termination factors Pcf11 and Rtt103 [34]
Tyr1P Impairs recruitment of termination factors during elongation [36]
Ser5P Recruits the mRNA capping enzymes and early termination factor Nrd1 [34]
Ser7P Co-occurs with Ser5P at the 5’ end of genes [33].
The exact function of Ser7P remains to be elucidated [34]
Table 1: Transcription factors and their functions are shown for factors analyzed in this work.
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Many rounds of initiation may be needed until the RNA–DNA hybrid reaches a length of 8
nucleotides, which leads to a considerable reduction of abortive initiation [39]. Promoter escape
is complete after synthesis of roughly 23 nucleotides downstream of the TSSs [39].
2.2 Elongation
Pol II undergoes a transition from intiation to elongation at about 150 nucleotides downstream
of the TSS [33]. During this transition initiation factors are exchanged with elongation factors
and Pol II is phoshporylated in Ser5 and Ser7 residues at its C-terminal domain (CTD), which
is required for 5’ capping of the nascent mRNA [31, 32, 33]. The CTD is a heptapeptide reapeat
(YSPTSPS) in the largest subunit of Pol II (Rpb1) which undergoes a specific sequence of post-
translational modifications during transcription also known as the CTD cycle [40]. The serine 5
phosphorylation at the CTD (introduced by the kinase Kin28, Figure 2) and the elongation factor
Spt5 help to recruit the mRNA-capping enzymes Cet1, Ceg1, and Abd1 [31, 32]. These proteins
catalyse three reactions which result in an addition of a 7-methyl-guanosine (m7G) cap to the 5’
end of the nascent mRNA [32], which protects it from degradation [41]. The cap is then bound
by the cap-binding complex which is important for recruitment of elongation factors Ctk1 and
Bur1 to promote elongation and capping enzyme release (Figure 2) [31]. After the exchange of
initiation with elongation factors at the 5’ transition Pol II undergoes Ser2 phophorylation at the
CTD by kinases Ctk1 and Bur1 [27,30,33]. Moreover Tyr1 CTD phosphorylation is introduced (in
human by c-Abl), which stimulates binding of elongation factor Spt6 and suppresses transcription
termination by impairing the recruitment of termination factors [36].
2.3 Termination
The first step of Pol II transcription termination takes place at the polyadenylation (pA) site,
which is a conserved hexamer with the consensus AAUAAA [42]. The pA site is recognized by spe-
cific factors, which process the RNA by endonucleolytic cleavage and polyadenylation [23,43,44].
In yeast, this is carried out by cleavage factor IA (CFIA), cleavage factor IB (CFIB), and cleavage
and polyadenylation factor (CPF) [23]. CFIA consists of Rna14, Rna15, Clp1 and Pcf11 [23],
which interacts with the serine 2 phosphorylation of the CTD [22] and the CPF [44]. The RNA
is cleaved by the CPF endonuclease Ysh1 and the polyA-tail (roughly 70 nt in yeast, 200 nt in
mammals) is added to the mRNA to protect it from 3’ degradation [22,44].
Transcription continues several hundred (yeast) or thousand (human) nt downstream of the pA
site [44]. Two major conditions are thought to contribute to destbilization and release of Pol II
from the DNA [44]: the speed of the Pol II elongation complex and the stability of the RNA:DNA
hybrid. There are two models for Pol II release from the DNA, but the exact mechanisms remain
unclear. The ’torpedo model’ assumes that an exonuclease degrades the RNA in 5′ → 3′ direction
after cleavage until it reaches and destabilizes the Pol II complex [45,46]. In the ’allosteric model’,
transcription of the pA site induces a destabilizing conformational change in the Pol II complex,
which causes Pol II realease and transcription termination [46,47].
There is another transcription termination pathway in yeast, which is dependent on Nrd1.
This pathway terminates transcription of snRNAs, snoRNAs, SUTs, CUTs, XUTs and several
ORFs [22, 24, 26, 48, 49]. Nrd1 binds the serine 5 phosphorylated CTD of Pol II [25, 50] and a
tetramer motif in the RNA [26, 49]. It interacts with the helicase Sen1 and Nab1 to promote
termination [51]. Unlike the pA-dependent termination pathway, transcripts terminated by the
Nrd1-dependent pathway are rapidly degraded by the nuclear exosome [22].
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Figure 2: Overview of the transcription cycle adopted from [34]. Pol II is recruited during the assembly
of the pre-initiation complex (PIC). PIC assembly is completed by binding of TFIIH whose subunit Kin28
phosphorylates the serine 5 residue (red, Ser5P) at the c-terminal domain (CTD) of Pol II during initiation.
Ser5P helps to recruit capping encymes (CE) which introduce a 7-methyl-guanosine (m7G) cap to the 5’
end of the nascent mRNA to protect it from degradation. Nrd1 binds the serine 5 phosphorylated CTD
of Pol II and a tetramer motif in the RNA. It interacts with the helicase Sen1 and Nab1 to promote
transcription termination of snRNAs, snoRNAs, SUTs, CUTs, XUTs and several ORFs. Productive
elongation involves phosphorylation of the serine 2 (cyan, Ser2P, by kinases Bur1 and Ctk1) and tyrosine
1 (green, Tyr1P, by human c-Abl) residues, while Ser5P is dephosphorylated. Tyr1P impairs recruitment
of termination factors during elongation. Ser2P recruits the polyadenylation (PA) machinery and 3’-
RNA processing and termination factors Pcf11 and Rtt103. The exonuclease complex (Exo) degrades
cleaved RNA in 5′ → 3′ direction, which triggers destabilization and release of the Pol II complex in the
torpedo model. The allosteric model assumes that a destabilizing conformational change is induced by
transcription of the poly-adenylation site.
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3 The histone code of transcription
Nucleosomes are the most basic unit of structural organization of the chromosomes in the nu-
cleus [2]. The core nucleosome consists of a protein octamer - formed by H2A, H2B, H3 and H4
- and 146 nucleotides (nt) of double-stranded DNA, which is wrapped around it. These occur in
an average distance of about 80 nt along the DNA, but distances can vary. The positioning of
nucleosomes is determined by DNA properties and DNA-binding proteins [2,52]. For instance the
SWI/SNF complex is a chromatin remodeler that can dislocate nucleosomes from the promoter
to make it accessible for transcription factors and polymerase [53]. Nucleosome depletion is a
hallmark of cis-regulatory regions and a strong periodic pattern of nucleosome positioning has
been observed downstream of the transcription start site [54,55].
Each core histone contains an N-terminal tail, which can be post-translationally modified. A
plethora of these histone tail modifications has been described [56]. For instance the H3 lysine 36
trimethylation (H3K36me3), H4 lysine 20 monomethylation (H4K20me1) have been shown to oc-
cur in gene bodys and are predictive for gene expression [57,58,59,60]. The H3 lysine 9 trimethy-
lation is a frequent modification in inactive heterochromatin and is implicated in chromatin
structure by binding of the heterochromatin-forming protein HP1 [61]. Another heterochromatic
modification is H3 lysine 27 trimethylation which is associated with transcriptionally repressed re-
gions [59]. H3 mono- and trimethylation at lysine residue 4 (H3K4me1 and H3K4me3) are present
at promoters and enhancers [62], which can be further distinguished into active and poised by
presence of repressive marks H3K27me3, H3K9me3 and active marks H3K9ac, H3K27ac [63,64].
Despite the fact that many histone modifications could be linked to different functions, the exact
mechanisms of how the ’histone code’ affects the associated biological processes remain largely
unclear [55].
4 High-throughput experimental assays
In this section a short overview of high-throughput assays and experimental techniques which are
analyzed in this work is given.
4.1 Microarrays
In order to understand genomic processes like transcription, high-throughput experimental tech-
niques are needed to measure genomic features and phenotypes like protein binding or RNA
expression in a genome-wide manner. The first assays to accomplish this were based on microar-
ray technology. Microarrys harbour thousands to millions of oligonucletides which are anchored
on their surface [65, 66]. The abundance of free DNA or RNA in a sample is measured by hy-
bridization to the immobilized oligonucleotides on its surface.
4.1.1 Transcriptome profiling using microarrys
The first mircroarray for gene expression measurement was developed in 1995 [67]. It was designed
to detect in parallel the expression of 45 genes in Arabidopsis thaliana. To this end, Arabidopsis
mRNA was reverse transcribed into cDNA which was labeled using a fluorescent dye. The
labeled cDNA was hybridized to the array and gene expression measurements were obtained by a
scanner. Two years later a microarray was developed to measure expression of 2,479 genes in S.
cerevisiae [68]. These early microarrays represented only a small fraction of oligonucleotides of
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the genomes of interest and therefore only provided a biased view of a genome. This limitation
was overcome by the develpment of whole genome microarrays (or tiling arrays), which covered
the complete genomic sequence of an organism [65].
In 2003, the first whole genome tiling array design was developed for Arabidopsis thaliana [69].
It covered 94% of the Arabidopsis genome on 12 arrays, each of which contained approximately
834,000 25-mer oligonucleotides. For the first time, the transcriptome could be measured in
an unbiased and genome-wide manner and 5,817 novel transcription units were discovered. In
2006, David et al. [70] developed a tiling array for S. cerevisiae that contained 6.5 million 25-mer
oligonucleotides which represented the full genomic sequence tiled at an average of eight nucleotide
intervals on each strand. This enabled genome-wide measurements in a four nucleotide resolution
for double-stranded and eight nucleotide resolution for strand-specific targets. Using this array
the authors quantified RNA expression of the complete yeast genome in rich media and found a
total of 85% of the genome to be expressed. Later this array was used to annotate thousands
of stable (stable unannotated transcripts, SUTs) and rapidly degraded RNAs (cryptic unstable
transcripts, CUTs) in the yeast genome and it was shown that pervasive transcription is generated
by bidirectional promoters [4].
4.1.2 ChIP-chip
ChIP-chip combines chromatin immunoprecipitation (ChIP) with hybridization on microarrays.
ChIP is a widely used method to detect and quantify protein-DNA binding in vivo [71,72]. First
protein complexes are cross-linked to DNA using formaldehyde. Then cells are harvested, lysed
and the chromatin is isolated. After cell lysis, the DNA is sheared into fragments. Immunopre-
cipitation with an antibody which is specific for the protein of interest is used to enrich DNA
fragments that are bound by it. Cross-links are then reversed, free DNA samples are isolated,
amplified and labeled with a dye. In the case of ChIP-chip, the DNA is then hybridized to the
microarray. Binding intensities to the oligonucleotides on the chip are detected by a scanner.
In 2000 the first for ChIP-chip studies measured binding of indiviual transcription factors in yeast
intergenic regions [73,74,75]. Later, this protocol was applied on a larger scale to infer the yeast
transcription regulatory network [76, 77], and to create a genome-wide map of nucleosomes [54]
and the pre-initiation complex in yeast [78]. The same yeast tiling array used for transcriptome
profiling developed in [70] was later applied with ChIP-chip to measure genome-wide occupancies
of transcription-related proteins in yeast [4, 31, 33, 36, 54], which are re-analyzed in this work
together with the expression data from Xu et al. [4] (see section 14).
4.2 Next-Generation Sequencing
One important limitation of whole genome microarrays was that their application was only feasible
on relatively small genomes. For larger genomes a high number of microarrays would be needed to
tile the entire genome, which made their use impractical for organisms like human [65]. Roughly at
the same time as tiling arrays were extensively used for whole genome analyses, massively parrallel
sequencing (so-called ’Next-Generation-Sequencing’) technologies began to emerge. In 2005-2007,
the first systems were released and applied to Whole Genome Sequencing (WGS) [79,80]. It did
not take long until Next-Generation-Sequencing was combined with other experimental assays.
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4.2.1 ChIP-Seq
In analogy to the ChIP-chip protocol, ChIP-Seq combines ChIP with Next-Generation-Sequencing.
Instead of hybridization with a microarray, the immunoprecipitated and amplified DNA fragments
are sequenced in a massively parallel manner. In 2007 three independent groups published proto-
cols combining ChIP with Next-Generation-Sequencing (ChIP-Seq) using the Illumina’s Solexa
system [59,60,81]. Barski et al. [59] and Mikkelsen et al. [60] used ChIP-Seq to measure covalent
histone modifications in human and mouse, while Johnson et al. [81] determined binding sites of
the neuron-restrictive silencer factor (NRSF) in human. While ChIP-chip and ChIP-Seq produce
highly reproducible results, ChIP-seq generally exhibits a better signal-to-noise ratio and detects
more and narrower peaks than ChIP-chip [82].
4.2.2 RNA-Seq and Dynamic Transcriptome Analysis
In 2008 two studies presented sequencing based methods for quantifying RNA expression (RNA-
Seq) in yeast [83] and mouse [84]. RNA-Seq measures the total RNA levels in a cell. However
these total RNA levels are the result of synthesis and degradation, which cannot be inferred from
standard RNA-Seq protocols. To address this problem, Dynamic Transcriptome Analysis was
developed (DTA) [85, 86]. During a DTA experiment, newly synthesized RNAs are labeled with
the nucleoside analog 4-thiouridine (4sU), which is incorporated into RNA during transcription.
The labeled RNAs are then biotinylated and purified using streptavidin-coated magnetic beads.
Labeled and unlabeled RNA fractions are quantified using microarrays [86] or Next-Generation-
Sequencing [26, 87], which is then used to estimate RNA synthesis and decay rates with kinetic
modeling. A clear advantage of DTA compared to standard transcriptomics is that the cellular
response to external stimuli can be observed at higher sensitivity and temporal resolution [86].
In this work a comprehensive map of the transcriptome in human K562 cells is derived from
transient transcriptome sequencing (TT-Seq), a new and improved protocol based on labeling
newly synthesized RNA using 4sU (see secion 16).
4.2.3 Detecting DNase hypersensitivity sites with DNase-Seq
Endonucleolyitc cleavage of DNA by Deoxyribonuclease I (DNase I) can be used to determine
accessible regions (i.e. not bound by nucleosomes) in the genome. The mapping of DNase
I hypersensitive sites (DHS) - i.e. sites that are sensitive to DNase I cleavage - is a tool to
determine potential regulatory regions [88, 89]. Combined with Next-Generation sequencing it
can be used to map these regions genome-wide [90, 91]. For instance the ENCODE Consortium
applied DNase-Seq to 125 human cell and tissue types to identify ∼2.9 million DHSs [92,93]. In
the first steps of DNase-Seq, cells are lysed, nuclei are isolated and the DNA is digested with
DNase I [90]. This leaves single-stranded overhangs in the DNA which are blunt ended by T4
DNA polymerase before ligation to a linker DNA. DNA fragments are attached to Dynal beads,
amplified by PCR and then sequenced. A computational analysis then identifies regions with
high density of DNase I cleavege sites [91]. However, a substantial amount of sequence specificity
of DNase I was observed in DNase-Seq data sets and thus care must be taken when interpreting
the results [94].
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5 Large-scale genome projects
Since the release of the human genome sequence several large-scale projects were initiated to
annotate functional elements in the DNA and understand their implications in human develop-
ment and disease [95,96,97,98]. To accomplish this task these projects generated and integrated
massive amounts of genome-wide experimental data. The next sections introduce two of these
large-scale projects from which data is used in this work to annotate regulatory elements in the
human genome (see section 15).
5.1 The ENCODE project
The Encyclopedia of DNA Elements (ENCODE) project was started in 2003 as a follow up to the
Human Genome Project to annotate all functional elements in the DNA [96]. The first phase (pilot
phase) focused on the annotation of a subset of 30 megabases (1%) of the human genome [96,99].
This subset (ENCODE pilot regions) consisted of 44 regions in human genome. Half of the
ENCODE pilot regions were selected manually and had to contain either well characterized genes
or functional elements or were required to have a high amount of comparative sequence data
available. During the pilot phase, experimental approaches were tested and then implemented in
the ’technology development phase’. After the release of the results of the ENCODE pilot phase
in 2007 [99], the third ’data production phase’ started to apply the established protocols and
measure a variety of biological features in the human genome. These included various techniques
for the analysis of genes and their transripts (e.g. RNA-Seq), transcription factors (e.g. ChIP-
Seq), chromatin features (e.g. ChIP-Seq or DNase-Seq), DNA methylation (e.g. Methyl-Seq)
and chromatin interactions (e.g. CHIA-PET) [100]. These were used for instance to annotate
regulatory elements (such as promoters and enhancers) [93, 101, 102, 103] or transcripts [104].
Overall the ENCODE project assigned a biological function to 80.4% of the human genome [93].
However, this conclusion lead to one of the major critiques of ENCODE and was attributed to
the loose use of the term ’function’ and other methodological flaws [105,106].
5.2 The Roadmap Epigenomics project
In 2008, the NIH Roadmap Epigenomics Mapping Consortium was launched with the goal to
define epigenomic maps in stem cells and primary ex vivo tissues, which include DNAmethylation,
histone modifications and RNA transcripts [95]. This effort was intended to generate a resource for
studies investigating human development, diversity and disease [107,108,109]. Recently Roadmap
Epigenomics data was combined with ENCODE data to annotate regulatory elements in 127 cell
types and tissues [110], revealing significant differences of chromatin features between various
group-wise comparison such as sex, tissue or cell type indicating the need for cell-type/tissue-
specific epigenomic maps [111].
6 Genomic data analysis with hidden Markov models
Hidden Markov models (HMMs) are a powerful tool for the analysis of longitudinal data and
therefore ideally suited for genomic data analysis. Here I quickly want to introduce the concept
and idea of a HMM.
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A formal definition of a HMM is given by [112,113]:
Definition. A hidden Markov model (HMM) is a tuple θ = (K, π, A,D,Ψ) such that
1. K is a finite set, the elements of which are called states.
2. The initial state distribution π = (πi)i∈K is a probability (row) vector, i.e., 0 ≤ πi ≤ 1,
i ∈ K, and
∑
i∈K πi = 1.
3. The transition matrix A = (aij)i,j∈K is a K × K (row) stochastic matrix, i.e., each row of
A is a probability vector.
4. The emission distributions Ψ = {ψi; i ∈ K} form a set of probability distributions on a
space D, the space of observations.
A HMM defines a probability distribution on a sequence of observations O = (o0, ..., oT ) of length
T+1. It assumes that each observation ot is emitted by a corresponding hidden (unobserved) state
variable st which can assume values in K. The value of st determines the probability of observing
ot by Pr(ot | st) = ψst(ot). The hidden variables are assumed to form a homogenous Markov
chain S = (s0, ..., sT ), with (time-independent) transition probabilities Pr(st = j | st−1 = i) = aij ,
i, j ∈ K, t = 1, ..., T , and with initial state distribution Pr(s0 = i) = πi, i ∈ K.
The following toy example illustrates how HMMs can be used to model transcription (Figure 3).
Let’s assume that we measured the binding signal of several transcription initiation, elongation
and termination factors at a protein coding genes. Initiation factors have a high binding signal
in promoter regions, but a low signal in the gene body. In contrast, elongation factors are high
in the gene body and low in promoter regions, etc.. Therefore each phase of transcription is
represented in the data by a specific combination of protein binding signals.
Now we relate above formal definition and parameters of the HMM to our example. A HMM
assumes that some observable variable (protein binding signal in our example) is generated by an
unobserved or ’hidden process’ (transcription in our example). This hidden process is assumed
to have a discrete number of states, the ’hidden states’. In our example the hidden states are
represented by the different phases of transription, e.g. initiation, elongation, termination. These
hidden states generate (or emit) the observations with a certain probability distribution (the
emission distribution). For instance in the ’initiation state’ we observe a different composition
of the transcription machinery (from the binding data) than in the elongation or termination
states. This is modeled by different probability distributions. Moreover, the hidden states occur
in a sequential order along a gene, usually in the order initiation ⇒ elongation ⇒ termination.
This sequential order is modeled by transition probabilities in the HMM. For instance in our
example the probability to transition from initiation to elongation is high but the probability to
transition from intiation directly to termination is zero (because it is not observed in the data).
In summary, a HMM allows us to explain and characterize the process of transcription as a series
of ’hidden (transcription) states’ directly from the protein binding data.
The observations in HMMs are not limited to binding data, but could also be the letters of a
DNA or protein sequence or gene expression data. The following section illustrates the wide
applicability of HMMs in genomics by giving a short overview of HMM-based methods in the
field.
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Figure 3: Example use of hidden Markov models to model transcription. (Left) The (toy) data was
measured for three transcription factor at gene X. The initiation factor exhibits high signals at the 5’ end
of the gene, the elongation factor has high signals in the gene body and the signal of the termination
factor increases towards the 3’ end of the gene. Up- and downstream of the gene, signals are low for all
three factors. (Middle) The signal distribution of all three factors can be modeled (in 5′ ⇒ 3′ direction)
using a hidden Markov model (HMM) with four states. The depicted graph represents the transition
probabilities (without self transitions) between the states learned from the toy example. Starting in an
unbound state (upstream of the gene), the model transition to the initiation, elongation and termination
state before returning to the unbound state (downstream of the gene). (Right) The model can then be
used to generate an annotation of the these states along the genomic sequence (depicted as colored boxes
below the signal tracks).
6.1 HMMs to detect functional elements in nucleic acid sequences
Early applications of HMMs in genomics were mainly used to find functional elements in the DNA.
In the 1990s the first HMM-based gene finding programs were developed [114,115]. Thereby, the
structure of genes was encoded by the transitions between hidden states of the model. For
instance the gene finder for E. Coli by Krogh et al. [114] used a sequence of three hidden states
to encode the start codon ATG (one state for each nucleotide). The last G in the start codon
then transititioned into a sequence of codon triplets modeling an exon, followed by states for the
stop codon. Over the past two decades new and improved HMM-based gene finding algorithms
were developed [116, 117, 118, 119]. Recently also RNA-Seq data was integrated into the models
[120,121].
One way to find potential functional elements (such as promoters, enhancers or genes) in the
DNA is to look for genomic regions which are conserved between species [122]. To this end the
so called phyloHMMs were developed which combine hidden Markov models with phylogenetic
models [122, 123]. These methods learn a HMM with states for ’conserved’ and ’not conserved’
regions in the genome. The emission distributions of the states are based on phylogenetic models
from a multiple sequence alignment [122]. The model is then used to compute a conservation
score for each genomic position.
The detection of cis-regulatory elements (CREs) or transcription factor bindig sites in DNA
sequences also is a problem that can be addressed with HMMs. The discovery of these elements
was previously done by exploiting phylogenetic information from sequence alignments [124, 125,
126] or by scanning the DNA with individual or combinations of transcription factor binding sites
modeled by a HMM [127,128,129]. The method byWong and Nielsen [124] for instance used a very
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simple approach to represent CRE structure in the HMM [124]. The model consists of two types
of states: the background states and the CRE states. The background states model the nucleotide
distribution of genomic background regions using relative nucleotide frequencies. The CRE states
consist of a set of transcription factor binding motifs, which are modeled using multiple subsequent
nucleotides (one state per nucleotide). More recently HMMs were also applied to de novo motif
discovery to infer transcription factor binding motifs from nucleic acid sequences [130].
6.2 HMMs and protein sequences
Another class of HMMs that should be shortly mentioned here are profile-HMMs, whch have
been applied extensively with protein sequences. For instance, they were used to classify proteins
into families [131], for domain classification of transcription factors [132] or the detection of
remotely homologuous proteins in sequence alignments [133]. Other HMM-based approaches
that work with protein sequences are secondary structure [134] and transmembrane topology
prediction [135].
6.3 Applications of HMMs to genome-wide high-throughput experiments
High-throughput experiments such as ChIP-chip or ChIP-Seq are often aimed at finding ’active’
and ’inactive’ (or ’bound’ and ’unbound’) regions. The prediction of these regions thorughout
the genome can be done with a simple two-state HMM, where one state models the active and
the other state the inactive regions. These can be for instance TF-bound [136,137,138,139], tran-
scribed [136,140] or methylated regions [141,142]. A more complex example is microMUMMIE for
binding site identification of microRNAs [143], which combines binding data with RNA sequence.
Another example application is the identification of copy number variations using multiple states
in the HMM for duplicated and depleted chromosomal regions [144,145,146].
6.4 Large-scale prediction of cis-regulatory elements
The discovery that genomic elements such as promoters and enhancers carry specific combinations
of histone modifications (see section 3) made it possible to use these features in an integrative
manner with HMMs to predict these elements genome-wide. Currently, the most popular al-
gorithms used for this task are based on HMMs. The ENCODE and Roadmap Epigenomics
projects used HMM-based methods to de novo infer ’chromatin states’ from ChIP-Seq of TFs
and histone modifications and DNase-Seq. Thereby a ’chromatin states’ defines a recurring com-
bination of histone modifications which are modeled with a probability distribution (the emission
distribution). The crucial difference between these methods lies in the choice of the emission
distribution. The first HMM-based methods to do this modeled combinations of histone modifi-
cations using multivariate normal distributions or nonparametric histograms [147,148,149]. The
following sections will shortly present three state-of-the-art methods which are widely used in
current genomics research.
6.4.1 ChromHMM
ChromHMM was applied by the ENCODE and Roadmap Epigenomics projects and various
other studies to generate chromatin state annotations in various human cell types and tissues
[93,103,110,150,151,152]. ChromHMM assumes multivariate independent Bernoulli distributions
as emissions to model the presence or absence of chromatin marks (i.e. histone modification, DHS,
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etc.) in 200bp bins along the genome. The emission probability of an observation vector ot given
hidden state st at position t is
Pr (ot|st) =
∏
d∈D
p
ot,d
st,d
(
1− pst,d
)ot,d
Thus, the data needs to be binarized for this model. The default approach used by ChromHMM
defines presence or absence of chromatin marks in a 200bp bin as the smallest discrete number
nd > 0 such that Pr (X > nd) < 10−4 where X is a Poisson random variable with mean λd =∑T
t=0 ot,d
T+1 [150]. But in principle any other binarization or peak-finding method can be used. Model
learning in ChomHMM is done on the complete genome of an organism using an incremental
version of the Expectation-Maximization (EM) algorithm [150, 153]. When applied to multiple
cell types or tissues, the data is concatenated into one ’artifical genome’ to learn a joint model
across cell types or tissues [93,102,103].
An obvious limitation of ChromHMM is that the quantitative information in the data is lost due
to the binariaztion. This might restrict the discrimination of features that exhibit presence of a
set of marks, but at different ratios. This is the for instance the case for promoters and enhancers
which have been shown to be marked by both H3K4me1 and H3K4me3, but at different ratios [62].
Moreover, all genomic positions with read counts below the binarization threshold are collapsed
into a ’silent state’, and the choice of the binarization cutoff is arbitrary, but crucial for the output
of the model [154].
6.4.2 Segway
Segway was applied in the ENCODE project to annotate chromatin states in the human genome
[93, 101, 102]. It is also the method of choice of the Ensembl Regulatory Build, which integrates
epigenomic data to annotate regulatory elements in a robust manner [155]. Formally Segway is
defined as a dynamic bayesian network. It is not exactly a HMM but has some similarity to
it [101]. Segway uses independent Gaussian distributions to model the sequencing data (each
track independently of each other) and therefore also relies on signal transformtation. This is
done by applying the inverse hyperbolic sine function ot = ln
(
ot +
√
o2t + 1
)
, normalization
and smoothing of the data [101, 102]. However the resulting data is still zero-inflated which can
cause singularity of the variance in low coverage states during model learning. This problem is
addressed in Segway by assuming a shared variance over states for a data track. Therefore the
emission probability of an observation vector ot given hidden state st at position t is
Pr (ot|st) =
∏
d∈D
1
σd
√
2π
e
−(
ot−µst,d)
2
2σ2
d
Segway was originally desinged to model the data in 1 bp resolution [101], but binning is also
possible [155]. In contrast to ChromHMM, Segway learns separate models when applied to
multiple cell types or tissues [102]. Limitations of Segway concern its speed, data preprocessing
and choice of emission function. In particular when applied in 1 bp resolution Segway is order
of magnitudes slower than ChromHMM and requires much more computational resources [154].
As for ChromHMM, the method used for signal transformation is arbitrary. Moreover the zero-
inflated distribution of the transformed data can be very different from a Gaussian distribution
[154] and the shared variance over states is a poteintially flawed and inflexible assumption about
the variance in the data.
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6.4.3 EpicSeg
More recently, EpicSeg (Epigenome Count-based Segmentation) was proposed to overcome lim-
itations of Segway and ChromHMM [154]. EpicSeg models the raw read counts in 200 bp bins
along the genome using a negative multinomial distribution and runs at a comparable speed as
ChromHMM [154]. Therefore - except for read mapping - it does not rely on preprocessing of
the data. The negative multinomial distribution can be defined as hierarchical model where read
counts ot follow a multinomial distribution with parameters pd, d ∈ D and O+t =
∑
d∈D ot,d
follows a negative binomial distribution with parameters mean µot,d, d ∈ D and rate parameter
r. The default mode of EpicSeg assumes a shared rate parameter r for all states, since free
rst parameters for all states might lead to ’unrealistic models where different states have wildly
different dispersion parameters’ [154]. The emission probability of an observation vector ot given
hidden state st at position t is
Pr (ot|st) = NegativeBinomial
(
O+t |st, r, µst,d
)
Multinomial (ot|st, pst,d)
=
Γ
(
r +O+t
)
O+t !Γ (r)
(
r
r + µst,d
)O+t (
1− r
r + µst,d
)r (∑
i∈D ot,d
)
!∏
d∈D (ot,d!)
∏
d∈D
p
ot,d
d
While having the advantage of modeling raw read counts and therefore omitting arbitrary pre-
processing steps, also EpicSeg makes a rigid assumption about the variance by assuming only one
shared rate parameter r for all states and data tracks.
7 Aims and scope of this thesis
As pointed out above (see section 6.4) current methods for genome segmentation have impor-
tant shortcomings. They are limited by unrealistic data distribution assumptions and variance
models. Moreover, they are not able to assign forward or reverse direction to states or properly
integrate strand-specific (e.g., RNA expression) with non-strand-specific (e.g., ChIP) data, which
is indispensable to accurately characterize directed processes such as transcription.
These issues are addressed in this thesis by developing the theory of bidirectional HMMs (bdHMMs)
which can integrate strand-specific with non-strand-specific data to infer directed genomic states
from genomic data de novo. Moreover, a more realistic emission model for count data from se-
quencing experiments is proposed with the GenoSTAN (Genomic STate ANnotation) algorithm.
This thesis can be divided into three parts with different applications of the developed methods
that address various reasearch questions related to transcription and its regulation.
In the first application, bdHMMs are applied to a set of 22 previously published ChIP-chip
and RNA expression measurements with tiling arrays to investigate the following questions (see
section 14):
• What are the different states of the transcription cycle?
• What is the composition of the transcription machinery in each state?
• Is the sequence of states universal for all genes?
The second application uses GenoSTAN with today’s largest compendium of chromatin assays
to identify promoters and enhancers in 127 human cell types and tissues (see section 15). This
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application aims at providing a reference map of promoters and enhancers with significantly
higher accuracy than previous maps, which is then used to address the following question:
• What biochemical and regulatory features characterize promoters and enhancers?
In the third application, GenoSTAN is used to study transcription in human K562 cells by map-
ping transcription units (TUs) from TT-Seq (a new and sensitive variant of RNA-Seq) data. TUs
are classified using the improved promoter and enhancer annotation, resulting in an annotation
of mRNAs, lincRNAs, enhancer RNAs, antisense RNAs, and promoter-associated RNAs. This
comprehensive map of stable and transient RNAs in human K562 cells is used to investigate the
following questions (see section 16):
• Are there differences in transcription of promoters and enhancers?
• What are potential determinants of transcript stability?
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Part II
Methods
8 Hidden Markov models
This section presents the theoretical basis for parameter learning and genomic state annotation
in GenoSTAN (Genomic STate AN notation), a hidden Markov model with Poisson-lognormal
and negative binomial emission distributions. GenoSTAN is implemented in the software package
STAN [113], which is available from Bioconductor [156]. For a formal definiton of HMMs see
section 6.
8.1 The Baum-Welch algorithm
The learning problem for HMMs consists in maximizing the marginal likelihood of the model:
θ̂ = argmax
θ
Pr(O; θ)
Parameter estimation in an HMM is commonly done using the Baum-Welch algorithm [153], an
expectation-maximization (EM) algorithm [157]. The EM algorithm is an iterative procedure
in which a target function Q
(
θ; θold
)
is maximized with respect to the parameters θ, given a
previous parameter guess θold. This algorithm will converge to a local maximum of the marginal
likelihood P (O; θ).
Before deriving parmeter updates we define some auxiliary terms [112]. The (full) likelihood of a
HMM is
Pr(O,S; θ) = Pr(O | S; θ) · Pr(S; θ)
=
T∏
t=0
Pr(ot | st; Ψ) ·
T∏
t=1
Pr(st | st−1; A) · Pr(s0; π)
=
T∏
t=0
ψst(ot) ·
T∏
t=1
ast−1st · πs0 (1)
Let θold = (K, π, A,D,Ψ) be a HMM. Let O = (o0, ..., oT ) be a sequence of observations. For
i, j ∈ K, t = 1, ..., T , we define the posterior probabilities
ζt(i, j) = Pr(st−1 = i, st = j | O; θold) (2)
γt (i) = Pr
(
st = i|O; θold
)
(3)
These posterior probabilities can be calculated efficiently using the forward probabilities αt(i) =
Pr(st = i, o1, ..., ot; θ
old) and the backward probabilities βt(j) = Pr(ot+1, ..., oT | st = j; θold),
i, j ∈ K. Forward and backward probabilities are calculated recursively.
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αt(i) = Pr(st = i, o1, ..., ot; θ
old)
=
∑
k∈K
Pr(st−1 = k, st = i, o1, ..., ot; θ
old)
=
∑
k∈K
Pr(ot | st = i; θold) · Pr(st = i | st−1 = k; θold) · Pr(st−1 = k, o1, ..., ot−1; θold)
= ψoldi (ot)
∑
k∈K
aoldki αt−1(k) (4)
for t = 1, ..., T , and α0(i) = πoldi ψ
old
i (o0). Similarly for the backward probabilities,
βt(j) = Pr(ot+1, ..., oT | st = j; θold)
=
∑
k∈K
Pr(ot+1 | st+1 = j; θold) · Pr(st+2 = k | st+1 = j; θold)
·Pr(ot+2, ..., oT | st+1 = k; θold)
= ψoldj (ot)
∑
k∈K
aoldjk βt+1(k) (5)
for t = T − 1, ..., 0, and βT (j) = ψoldj (oT ). It follows that
ζt(i, j) =
αt(i)a
old
ij βt+1(j)ψ
old
j (ot+1)∑
k∈K αt(k)βt(k)
(6)
and
γt(i) =
αt(i)βt(i)∑
k∈K αt(k)βt(k)
(7)
Note that the quantities ζt(i, j) and γt(i) are always non-negative. The target function Q
(
θ; θold
)
is defined as the expectation of the log likelihood Pr(O,S; θ), where expectation is taken with
respect to the unknown hidden state sequence S and its posterior distribution Pr(S | O; θold),
Q
(
θ; θold
)
=
∑
S
Pr
(
S|O; θold
)
log Pr(O,S; θ)
=
∑
S
Pr
(
S|O; θold
){
log πs0 +
T∑
t=1
log ast−1st +
T∑
t=0
logψk(ot)
}
(8)
8.2 Updates of the initial state and transition probabilities
To get updates for the initial state probabilities π, we need to maximize Q
(
θ; θold
)
under the
constraint
∑
i∈K πi = 1. The Lagrange multiplier λ
(
1−
∑
k∈K πk
)
is introduced and the partial
derivatives of ∂∂πiQ
(
θ; θold
)
, i ∈ K are set to zero with respect to πi. This leads to the parameter
updates [112]:
πi = γ0 (i)
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We introduce Lagrange multipliers λk
(
1−
∑
l∈K akl
)
, k ∈ K to derive estimates for the trainsition
probabilities aij . Setting the partial derivatives of ∂∂aijQ
(
θ; θold
)
with respect to aij to zero, leads
to parameter updates [112]:
aij =
∑T
t=1 ξt (i, j)∑T
t=1 γt−1 (i)
8.3 Poisson-lognormal and negative binomial emissions
The Poisson-lognormal and the negative binomial distribution can be thought of as extensions of
the Poisson distribution that allow for greater variance. We will now motivate both distributions
from a Poisson distribution with a prior on the mean of the Poisson.
Suppose that X ∼ Poisson(x|Λ) is a Poisson random variable and Λ ∼ Gamma (λ|α, β). From
this we can derive the negative binomial with success rate p and size r [158]:
Pr (X = x|α, β) =
∞̂
0
Poisson (x|λ)Gamma
(
λ|α = r, β = p
1− p
)
dλ
=
∞̂
0
λx
x!
e−λλr−1
e
−λ 1−p
p(
p
1−p
)r
Γ (r)
dλ
=
Γ (r + x)
x!Γ (r)
px (1− p)r where r > 0, p ∈ [0, 1]
In order to increase interpretability in the context of read counts, we re-parameterize this with
mean µ = r(1−p)p :
Pr (X = x|µ, r) = Γ (r + x)
x!Γ (r)
(
r
r + µ
)x(
1− r
r + µ
)r
where µ > 0
The Poisson-lognormal distribution can be motivated likewise. Assume that X ∼ Poisson(x|Λ)
is a Poisson random variable and Λ ∼ N (log (λ) |µ, σ). Then the Poisson-lognormal is given
by [159]:
Pr (X = x|µ, σ) =
∞̂
0
Poisson (x|λ)N (log (λ) |µ, σ) dλ
=
√
2πσ2
x!
∞̂
0
λx−1e−λe−
(log(λ)−µ)2
2σ2 dλ
A closed form solution for this distribution does not exist. Thus numerical integration is needed
to calculate probabilities, which is done using the R package poilog [160,161].
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8.3.1 Parameter updates
Assuming that the components ot,d, d ∈ D, of a single observation ot are independent, and
hence ψk(ot) =
∏
d∈D ψk,d(ot,d). The value of st determines the probability of observing ot by
Pr(ot | st) = ψst(ot). HMM learning is carried out using the Baum-Welch algorithm [112]. The
optimization problem for the paramters of a single emission distribution ψi,d can be written as
arg max
ψi,d
T∑
t=0
Pr
(
st = i|O; θold
)
logψi,d (ot,d) ,
where Pr(st = i | O; θold) is calculated efficiently by the Forward-Backward algorithm, and ψi,d is
maximized within the class of negative binomial or Poisson-lognormal distributions. An analytical
solution for this problem does not exist. Thus, we resort to numerical optimzation. As indicated
by [154], above formula can be very costly to compute, since the function needs to evaluate a
sum over the complete observation sequence (i.e. the complete binned genome) in each iteration.
However, computations are greatly simplified by grouping together observations ot,d with the
same count number. Let Cd be the set of unique counts in dimension d. Then the following terms
can be precomputed for all c ∈ Cd before optimization:
f (c) =
∑
t; ot,d=c
Pr
(
st = i|O; θold
)
The objective function becomes
arg max
ψi,d
∑
c∈Cd
f (c) logψi,d (c)
which avoids redundant calculations of ψi,d(ot), t = 0, ..., T , and greatly reduces complexity since
|Cd|  T .
8.3.2 Correction for library size
The sequencing depth can be very different between experiments. To address this problem pre-
computed scaling factors were used to correct for varying sequencing depths for a data track
between cell types. In this work, the ’total count’ method is used [162]. Let L be the set of cell
types and rd,l the number of reads of data track d ∈ D in cell line l ∈ L. The scaling factor is
then computed as
sd,l =
rd,l∑
k∈L rd,k
·
∑
k∈C rd,k
|L|
The probability of an observation ot,l is calculated as Pr
(
ot,l| µsd,l , r
)
in the case of negative
binomial and Pr
(
ot,l| log
(
µ
sd,l
)
, σ
)
in the case of Poisson-lognormal emissions.
8.3.3 Initialization
Initialization of model parameters is crucial for HMMs since the EM algorithm is a gradient
method which converges to a local maximum. K-means is a widely used approach to derive an
initial clustering to estimate model parameters [112]. In order to make this approach applicable to
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sequencing data, we added a pseudocount and log-transformed the data before k-means clustering.
However, without further processing k-means rarely converged and the procedure was slow on
the complete data set. To address these issues, we further processed and filtered the data. First,
a threshold for signal enrichment for each data track is calculated using the default binarization
approach of ChromHMM [150]. The threshold is the smallest discrete number nd > 0 such that
Pr (X > nd) < 10
−4 whereX is a Poisson random variable with mean λd =
∑T
t=0 ot,d
T+1 . All ot,d < nd
were set to 0, which improved convergence of k-means. To improve the speed, all genomic bins
ot,d where ∀d ∈ D : ot,d = 0 were removed and defined as a ’background cluster’. K-means was
then run on the rest of the data with |K| − 1 clusters. This clustering (the ’background’ and
k-means clusters) was then used to derive an initial estimate of emission function parameters.
Initial state and transition probabilities were initialized uniform.
8.4 The optimal hidden state sequence
There are two popular ways to infer the optimal hidden state sequence S of a HMM given an
observation sequence O. One approach simply takes the state which maximizes the posterior
probability at each position [112]:
st = arg max
i
γt (i)
Alternatively one can calculate the optimal hidden state sequence S such that Pr (S,O|θ) is
maximized. This is also known as the Viterbi algorithm (the optimal S is then referred to as the
viterbi path) [112, 163]. To this end, δt (i) recursively computes the maximum probability of a
state sequence that ends in st = i:
δt+1 (j) = max
i
δt (i) aijψj (ot+1)
δt (i) = max
s1,s2,...,st−1
Pr (s1, s2, ..., st = i|θ)
δ0 (i) = πiψi (o0)
The optimal hidden state path is then obtained via backtracking [112,163].
9 Bidirectional hidden Markov models
A bdHMM is a HMM which satisfies three additional conditions. The first two conditions deal
with the structure of the underlying hidden Markov chain, and the last condition considers the na-
ture of observations. As will be shown in the subsequent paragraph on the semantic of bdHMMs,
these conditions are by no means ad hoc.
Definition.
A bidirectional hidden Markov model (bdHMM) is a tuple θ = ((K, iK), π, A, (D, iD),Ψ)
such that (K, π, A,D,Ψ) is a HMM, iK : K → K, k 7→ k̄ and iD : D → D, o 7→ ō are involutions
(i2K = id, i
2
D = id), and the following symmetry conditions hold:
1. Generalized detailed balance: The transition matrix A and the initial state distribution π
satisfy
πiaij = πj̄aj̄ī , i, j ∈ K (9)
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2. Initiation symmetry : The initial state distributionπ satisfies
πi = πī , i ∈ K (10)
3. Observation symmetry : Ψ satisfies
ψi(o) = ψī(ō) , i ∈ K, o ∈ D (11)
9.1 The semantic of bdHMMs
Why did we choose (9), (10), and (11) as the defining properties of a bdHMM? In order to
motivate our choice, let θ = ((K, iK), π, A, (D, iD),Ψ) be a bdHMM. By initiation symmetry and
generalized detailed balance,
(πA)j =
∑
i∈K
πiaij =
∑
i∈K
πj̄aj̄ī = πj̄ = πj , j ∈ K,
which proves πA = π. In other words, the initial state distribution π of a bdHMM is always
a stationary state distribution of A. It might be surprising that the initital state distribution
has to match the steady-state probabilities. This is however an uncritical constraint in practical
applications, for two reasons. First, low complexity regions (unassembled regions, repeat regions,
telomeres, centromeres, etc.) lead to frequent large stretches of missing values. Hence, the model
is not run on complete chromosomes, but on the remaining regions with complete data. Therefore,
taking the steady-state probability as initial probability is a reasonable modeling assumption.
Second, these regions are typically long enough so that the initial state distribution has minimal
influence on genomic state annotation.
Moreover, generalized detailed balance and initiaion symmetry together imply that the relation
P (st−1 = i, st = j) = P (st−1 = i) · P (st = j | st−1 = i) = πiaij
= πj̄aj̄ī = P (st−1 = j̄) · P (st = ī | st−1 = j̄)
= P (st−1 = j̄, st = ī) (12)
holds for all states i, j ∈ K and all positions t = 1, ..., T . This is a most natural condition as it
says that at any position of the state sequence, the probability of consecutively observing states i
and j equals that of observing the respective conjugate states in reversed order. Vice versa, (12)
obviously implies generalized detailed balance. Under the mild assumption that limt→∞(πAt)
always exists (this is the case, e.g., if the matrix A is ergodic, see [164]), it can be shown that
(12) also implies initiation symmetry: By induction, using
P (st = j) =
∑
i
P (st−1 = i, st = j) =
∑
i
P (st−1 = j̄, st = ī) = P (st−1 = j̄) (13)
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it follows that P (st = j) =
{
πj if t is even
πj̄ if t is odd
. Therefore,
πj = lim
t→∞
P (s2t = j) = lim
t→∞
(πA2t)j = lim
t→∞
(πA2t+1)j = πj̄ (14)
which is exactly condition (10). Hence the natural condition (12) is essentially equivalent to (9)
and (10). The reason for using the latter two conditions for the definition of a bdHMM is that
they are simple relations in terms of the model parameters π and A.
Bidirectional HMMs model directional processes in a sequence of observations. It is reasonable
to expect that an observation contains information about the directionality of the underlying
process that generated it. The involution iD is meant to map an observation o ∈ D to its so-
called conjugate observation ō = iD(o), which denotes the corresponding observation that one
would make if the observation sequence were viewed from the opposite direction. E.g., in the
case of genomic measurements, D is modeled as D = D0 × D+ × D−, the Cartesian product
of a space D0 of non strand-specific observations (e.g. ChIP measurements of protein binding),
a space D+of forward strand-specific observations (like RNA transcription originating from the
forward strand), and a corresponding set D− of reverse strand-specific observations. The forward
and reverse strand-specific observations are paired in the sense that D+ = D−. The involution iD
acts as the identity on D0 and it swaps the strand-specific observations, iD : o = (o0, o+, o−) 7→
ō = (o0, o−, o+). In hidden Markov models, observations will be emitted from hidden states
that may indicate typical processes occurring in forward or in reverse direction, or undirectional
processes. The involution iK splits the states K of the HMM into undirected states (denoted by
K0) - the fixed points k = k̄ of ik - and directed states which occur in pairs (k, k̄), k 6= k̄ of
’conjugate’ or ’twin’ states. One member of such a pair is deemed to be involved in forward, the
other in reverse directional processes (note that at this point we do not specify which of the two
does what). The forward states are denoted by K+, the reverse states by K−. The observation
symmetry condition (11) merely ensures that conjugate directed states encode essentially the
same probability distribution, up to reversal of the observations.
Note that if iK = id is the identity map, condition (3) is void, and condition (2) reduces to
the common detailed balance relation for reversible HMMs. If additionally the involution iD is
the identity map, condition (5) is also void. Thus, a bdHMM θ = ((K, id), π, A, (D, id),Ψ) is
nothing but a reversible HMM, i.e., an HMM which additionally satisfies the (standard) detailed
balance relation πiaij = πjaji, i, j ∈ K. It follows that our algorithms for bdHMM learning will
immediately apply to reversible HMMs.
Given an observation sequence O = (ot)t=0,...,T , let Orev = (orevt = ōT−t)t=0,...,T denote the ’re-
versed’ observation sequence obtained by taking conjugates of all observations and reversing their
order. Similarly, given a hidden state sequence S = (s0, ..., sT ), let Srev = (srevt = s̄T−t)t=0,...,T
denote the ’reversed’ hidden state sequence. Verify that
Pr(S; θ) = πs0
T∏
t=1
ast−1st
(9)
= πsT
T∏
t=1
as̄ts̄t−1
(10,9)
= πs̄T
T∏
t=1
as̄T−(t−1)s̄T−t = πsrev0
T∏
t=1
asrevt−1srevt
= Pr(Srev; θ) (15)
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Moreover,
Pr(O | S; θ) =
T∏
t=0
ψst(ot)
(11)
=
T∏
t=0
ψs̄t(ōt)
=
T∏
t=0
ψs̄T−t(ōT−t) =
T∏
t=0
ψsrevt (o
rev
t )
= Pr(Orev | Srev; θ) (16)
Equations (15) and (16) imply
Pr(O,S; θ) = Pr(O | S; θ) ·Pr(S; θ) = Pr(Orev | Srev; θ) ·Pr(Srev; θ) = Pr(Orev,Srev; θ) (17)
and
Pr(S | O; θ) = Pr(Srev | Orev; θ) (18)
Finally, a bdHMM is reversible in the generalized sense,
Pr(O; θ) =
∑
S
Pr(O,S; θ) =
∑
S
Pr(Orev,Srev; θ)
=
∑
Srev
Pr(Orev,Srev; θ) = Pr(Orev; θ) (19)
The second-last equality in (19) holds because if S runs over all possible state sequences, then so
does Srev. The need for a model satisfying the natural condition (17) motivated the development
of bdHMMs, and indeed condition (17) is almost their defining property: We mention without
proof that under very mild assumptions on the probability distributions Ψ, any HMM satisfying
(17) is a bdHMM.
9.2 Learning of the transition matrix and the initial state distribution
In this paragraph, we will derive an EM algorithm for the learning of the bdHMM parameters A,
π. Let θold = ((K, iK), πold, Aold, (D, iD),Ψold) be a bdHMM. It can be shown that Q
(
θ; θold
)
is
a lower bound of the marginal likelihood function Pr(O; θ) which touches the likelihood function
at θ = θold, i.e., Q(θold; θold) = Pr(O; θold) [157]. These properties guarantee that the iterative
maximization of Q leads to a local maximum of Pr(O; θ). We want to maximize Q with respect
to A and π under the constraints of a bdHMM. Using the posterior probabilities (2) and (3), and
summarizing the ψk terms into one constant c which does not depend on A or π, the modified
target function Q assumes a convenient form. The quantity Q is calculated in the E-step,
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Q
(
θ; θold
)
=
∑
S
Pr
(
S|O; θold
){ T∑
t=1
log ast−1st
}
+
∑
S
Pr
(
S|O; θold
)
{log πs0}+ c
=
∑
st−1∈K
∑
st∈K
Pr
(
st−1, st|O, θold
){ T∑
t=1
log ast−1st
}
+
∑
st−1∈K
Pr
(
s1|O, θold
)
{log πs0}+ c
=
∑
k∈K
∑
l∈K
T∑
t=1
ζt (k, l) log akl +
∑
k∈K
γ1(k) log πs0 + c (20)
We calculate the Jacobian matrix and the Hessian matrix of Q and show that Q is a convex
function.
∂
∂aij
Q̃
(
θ; θold
)
=
1
aij
T∑
t=1
ζt (i, j) (21)
∂
∂akl
∂
∂aij
Q̃
(
θ; θold
)
=
{
− 1
a2ij
∑T
t=1 ζt (i, j) ≤ 0 if (k, l) = (i, j)
0 else
(22)
The Hessian matrix is a diagonal matrix with non-positive diagonal entries, hence it is negative
semidefinite. This means that Q is concave. The maximization of Q is performed under the
constraints that π is a probability vector, A is a stochastic matrix, and that initiation symmetry
and generalized detailed balance holds. Unfortunately, these constraints define a non-convex
optimization domain. Still, powerful numerical solvers for concave functions exist. In our case,
we used the ipopt solver [165] and Rsolnp [166]. Transition probabilities might become very
small or even 0, which may cause problems for the optimization since the lower boundary for
the parameters is 0. Numerical optimizers tend to become very slow or even fail to converge
at the boundary of the solution space. To ensure numerical stability and proper convergence,
we set state transitions aij = 0 that drop below a certain cutoff
∑T
t=1 ξt (i, j) < c. When the
algorithm approximates a point of convergence it becomes less and less likely for a transition to
be removed. The EM-algorithm will find an optimal point with the additional constraints that
some transitions are 0. The numerical optimization approach becomes slow for very large data
sets and for a high number of hidden states. In our second approach, we therefore introduce a
modified lower bound function Q̃(θ; θold) which can be maximized analytically and hence very
efficiently. We iterate this maximization process in the same fashion as in the EM algorithm.
Although we were not able to prove convergence of the parameter sequence, this was always the
case in practice. Moreover, the results obtained by our heuristic were always identical to those
obtained by the numerical solver. Our heuristic is substantially faster, for our yeast data (section
10 and 14) with |K| = 20 states, we achieved an acceleration by a factor of about 25.
Given a bdHMM parameter set θ = ((K, iK), π, A, (D, iD),Ψ), we define the bdHMM parameter
set θ̄ = ((K, iK), π̄, Ā, (D, iD), Ψ̄), where π̄i = πī, āij = aīj̄ , ψ̄i(o) = ψī(o), i, j ∈ K, o ∈ D. The
modified target function is defined as
Q̃
(
θ; θold
)
= Q(θ; θold) +Q(θ; θ̄old) (23)
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where Q is defined as in (8). Since both Q terms in the sum in (23) are, up to some additive
constant, lower bounds of the marginal likelihood function Pr(O; θ), so is Q̃(θ; θold).
For S = (s0, ..., sT ) let S̄ = (s̄0, ..., s̄T ). It is elementary to verify that
Pr(O,S; θ) = πs0
T∏
t=1
ast−1st
T∏
t=0
ψst(ot)
= π̄s̄0
T∏
t=1
ās̄t−1s̄t
T∏
t=0
ψ̄s̄t(ot) = Pr(O, S̄; θ̄) (24)
From (24) we deduce that
Pr(st−1 = i, st = j | O; θ̄old) = Pr(st−1 = ī, st = j̄ | O; θold) = ζt(̄i, j̄) (25)
and
Q(θ; θ̄old) =
∑
st−1∈K
∑
st∈K
Pr
(
st−1, st|O, θ̄old
){ T∑
t=1
log ast−1st
}
+ c
=
∑
k∈K
∑
l∈K
(
T∑
t=1
ζt
(
k̄, l̄
))
log akl + c (26)
Equations (20) and (26) imply
Q̃
(
θ; θold
)
= Q(θ; θold) +Q(θ; θ̄old) + c
=
∑
k∈K
∑
l∈K
T∑
t=1
(
ζt (k, l) + ζt
(
l̄, k̄
))
log akl + c
To maximize Q̃ under the constraint(s) that A is a stochastic matrix, we introduce Lagrange
multipliers λk
(
1−
∑
l∈K akl
)
, k ∈ K, and rewrite Q̃ as
Q̃
(
θ; θold
)
=
∑
k∈K
∑
l∈K
T∑
t=1
(
ζt (k, l) + ζt
(
l̄, k̄
))
log (akl) +
∑
k∈K
λk
(
1−
∑
l∈K
akl
)
+ c (27)
For i, j ∈ K, we set the partial derivatives of Q̃ with respect to aij to zero,
0 =
∂
∂aij
Q̃
(
θ; θold
)
=
1
aij
T∑
t=1
(ζt (i, j) + ζt (j̄, ī)) − λi (28)
Multiplication by aij and summation over all equations j ∈ K leads to
λi
∑
j∈K
aij︸ ︷︷ ︸
1
=
T∑
t=1
(∑
j∈K
ζt (i, j)︸ ︷︷ ︸
γt−1(i)
+
∑
j∈K
ζt (j̄, ī)︸ ︷︷ ︸
γt (̄i)
)
λi =
T∑
t=1
(γt−1 (i) + γt (̄i)) (29)
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After substitution of (29) into (28), we solve for aij .
aij =
1
λi
T∑
t=1
(ζt (i, j) + ζt (j̄, ī)) =
∑T
t=1 (ζt (i, j) + ζt (j̄, ī))∑T
t=1 (γt−1 (i) + γt (̄i))
, i, j ∈ K (30)
Let
πi =
1
2T
T∑
t=1
(γt−1 (i) + γt (̄i)) , i ∈ K
Then π is a probability vector which together with A satisfies detailed balance,
πiaij =
1
2T
T∑
t=1
(ζt (i, j) + ζt (j̄, ī)) = πj̄aj̄ī , i, j ∈ K
Further, π almost satisfies initiation symmetry:
|πi − πī| =
1
2T
‖γT (̄i)− γT (i) + γ0(i)− γ0(̄i)‖ ≤
1
T
, i ∈ K
Although the vector π does not exactly satisfy initiation symmetry, the amount by which this
symmetry is violated is generally substantially smaller than 1T . This difference is negligible for
large T, i.e., for long observation sequences.
We have developed two strategies: The first, computer-intensive strategy is to do numerical
optimization using standard solvers; the second strategy is a fast heuristic. Both methods in
practice lead to the same results, and they are implemented in our R/Bioconductor software
package STAN [113].
9.3 Parameter updates for multivariate gaussian emissions
The emissison distributions Ψ are also updated by maximizing the original target function Q in
Equation (8). Summarizing irrelevant terms in a constant c, we have
Q
(
θ, θold
)
=
∑
k∈K
T∑
t=0
γt (k) log (ψk (ot)) + c
We assume multivariate Gaussian emission probabilities, ψi(ot) = N (ot;µi,Σ(i)), i ∈ K, with
mean µi ∈ RD and covariance matrix Σ(i) ∈ RD×D. We have implemented bdHMM with mul-
tivariate Gaussian emission probabilities, since they are appropriate distributions for microarray
data on a log or quasi-log scale [167]. Moreover, the covariance matrix of multivariate Gaussians
allows modeling correlations between factors in each state. This is important because factor oc-
cupancies tend to scale with the gene expression level. Such dependencies are captured by the
covariance matrix. Application to sequencing-based datasets can be done by transforming the
data such that it approximately follows a normal distribution [101,147].
We choose to model the emission probabilities ψi(ot) = P (ot | st = i), i ∈ [1;K], as multivariate
Gaussians, specified by the parameters µi,Σi with mean µi ∈ RD and covariance matrix Σi ∈
RD×D,
ψi(ot) = N (ot|µi,Σi) =
1
(2π)
D
2 · |Σi|
1
2
· exp
(
−1
2
(
ot − µi
)
T ·
(
Σi
)−1 · (ot − µi))
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Partial derivatives ∂
∂µi
log (ψi (ot)) and ∂∂(Σi)−1 log (ψi (ot)) are:
∂
∂µi
log (ψi (ot)) =
(
ot − µi
)T (
Σi
)−1
∂
∂ (Σi)−1
log (ψi (ot)) =
Σi
2
−
(
ot − µi
) (
ot − µi
)T
2
Making use of emission symmetry ψi(o) = ψī(ō), we calculate partial derivatives
∂
∂µi
Q
(
θ, θold
)
:
∂
∂µi
Q
(
θ, θold
)
=
∂
∂µi
[∑
k∈K
T∑
t=1
γt (k) log (ψk (ot))
]
=
T∑
t=1
γt (i)
∂
∂µi
[log (ψi (ot))] +
T∑
t=1
γt (̄i)
∂
∂µi
[log (ψi (ōt))]
=
T∑
t=1
γt (i)
(
ot − µi
)T (
Σi
)−1
+
T∑
t=1
γt (̄i)
(
ōt − µi
)T (
Σi
)−1
We set this to 0 and solve for µi:
0 =
T∑
t=1
γt (i)
(
ot − µi
)T (
Σi
)−1
+
T∑
t=1
γt (̄i)
(
ōt − µi
)T (
Σi
)−1
0 =
T∑
t=1
[
γt (i)
(
ot − µi
)
+ γt (̄i)
(
ōt − µi
)]
0 =
T∑
t=1
[γt (i) ot + γt (̄i) ōt]−
µi
(
T∑
t=1
[γt (i) + γt (̄i)]
)
µ̂i =
∑T
t=1 [γt (i) ot + γt (̄i) ōt]∑T
t=1 [γt (i) + γt (̄i)]
And thus:
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µ̂i =

∑T
t=0[γt(i)ot+γt (̄i)ōt]∑T
t=0[γt(i)+γt (̄i)]
if i is directed∑T
t=0 γt(i)ot∑T
t=0 γt(i)
if i is undirected
Next, we calculate partial derivatives ∂
∂(Σi)−1
Q
(
θ, θold
)
:
∂
∂ (Σi)−1
Q
(
θ, θold
)
=
∂
∂ (Σi)−1
[∑
k∈K
T∑
t=1
γt (k) log (ψk (ot))
]
=
T∑
t=1
γt (i)
(
Σi
2
−
(
ot − µi
) (
ot − µi
)T
2
)
+
T∑
t=1
γt (̄i)
(
Σi
2
−
(
ōt − µi
) (
ōt − µi
)T
2
)
Setting this to 0 and solving for Σi yields:
0 =
T∑
t=1
γt (i)
(
Σi
2
−
(
ot − µi
) (
ot − µi
)T
2
)
T∑
t=1
γt (̄i)
(
Σi
2
−
(
ōt − µi
) (
ōt − µi
)T
2
)
0 = Σi
T∑
t=1
[γt (i) + γt (̄i)]−
T∑
t=1
[
γt (i)
(
ot − µi
) (
ot − µi
)T
+ γt (̄i)
(
ōt − µi
) (
ōt − µi
)T ]
Σ̂i =
∑T
t=1
[
γt (i)
(
ot − µi
) (
ot − µi
)T
+ γt (̄i)
(
ōt − µi
) (
ōt − µi
)T ]∑T
t=1 [γt (i) + γt (̄i)]
Therefore,
Σ̂i =

∑T
t=0
[
γt(i)(ot−µi)(ot−µi)
T
+γt (̄i)(ōt−µī)(ōt−µī)
T
]
∑T
t=0[γt(i)+γt (̄i)]
if i is directed∑T
t=0 γt(i)(ot−µi)(ot−µi)
T∑T
t=0 γt(i)
if i is undirected
9.4 De novo inference of state direction
Let k be a directed state in a bdHMM. We introduce dirk, a measure for the direction of state
k which is based on the posterior probabilities for observing k respectively its conjugate k̄ at
positions t = 0, ..., T .
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dirk =
∑T
t=0
∣∣Pr (st = k|O, θ)− Pr (st = k̄|O, θ)∣∣∑T
t=0
(
Pr (st = k|O, θ) + Pr
(
st = k̄|O, θ
)) (31)
The score will be low if the differences in the probability for observing the forward twin state
and the probability for observing the respective reverse twin state is low. It will be high if this
differences is large and thus the direction of twin states is well distinguishable. In order to account
for the overall probability of state k, the sum of absolute differences in the nominator in (31)
is normalized by the sum over all positions t of the posterior probabilities for observing k or k̄.
The direcitionality score is used to infer whether a directed state pair (k, k̄) of a bdHMM truely
contains directional information, or whether it should be collapsed into one undirected state of a
new bdHMM. Our rule of thumb is to collapse a directed state pair if dirk < 0.5 (see also section
14 and Supplementary Figure 5 in [113]).
9.5 Initialization of bdHMMs
If strand-specific data is available, the number of directed and undirected states can be set in an
intuitive manner in advance. For the yeast data, the strand-specific expression data was first split
into regions expressed on either the + or - strand and unexpressed regions. Directed state means
were initialized as a k-means clustering from the expressed regions while undirected states were
initialized using k-means on the unexpressed regions. We found that initialization by k-means
works very well and generally converges to a higher likelihood than multiple random starts, in
agreement with [112]. To not introduce further biases towards the k-means initialization and
allow the EM to explore solutions which are further from it, covariance matrices were initially set
to the covariance of the whole data and transition and initial state probabilities were initialized
uniform.
In the absence of strand-specific data and without directionality annotation, we suggest to apply
the directionality score that can be used as a posterior criterion to merge twin states into one
undirected state, as we demonstrate for the CD4 T-cell chromatin modification data.
9.6 Simulations
The performance of bdHMM regarding parameter inference and state annotation on data not used
for training was assessed using simulated datat sets. For this purpose, we construct a transition
matrix A = (aij)i,j∈K and an initial state distribution π = (πi)i∈K which satisfy generalized
detailed balance and initiation symmetry. Choose an arbitrary transition matrix A∗ =
(
a∗ij
)
i,j∈K
and a stationary distribution π∗ = (π∗i )i∈K , π
∗A∗ = π∗.
aij =
π∗i a
∗
ij + π
∗
j̄
a∗
j̄ī
π∗i + π
∗
ī
πi =
1
2
(π∗i + π
∗
ī )
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Verify that π is a probability vector that satisfies initiation symmetry:∑
i∈K
πi =
1
2
∑
i∈K
π∗i +
1
2
∑
i∈K
π∗ī =
1
2
+
1
2
= 1
πī =
1
2
(π∗ī + π
∗
ī
) =
1
2
(π∗i + π
∗
ī ) = πi
Furter, A is a stochastic matrix,
∑
j∈K
aij =
1
π∗i + π
∗
ī
∑
j∈K
π∗i a
∗
ij +
∑
j∈K
π∗j̄a
∗
j̄ī

=
1
π∗i + π
∗
ī
(π∗i + (π
∗A∗)̄i)
=
1
π∗i + π
∗
ī
(
π∗i + π
∗
ī
)
= 1
and A together with π satisfy generalized detailed balance,
πiaij =
1
2
(
π∗i a
∗
ij + π
∗
j̄a
∗
j̄ī
)
= πj̄aj̄ī
We mention that A is ergodic if A∗ is ergodic.
To make our simulations realistic, we sample A∗ as follows: Introduce an arbitrary linear order
’≤’ on K+ (this order is meant to describe the preferential order of events for the directed states).
Then,
a∗ij ∼

U (0.95, 0.99) if i = j
U (0.1, 0.7) if (i, j ∈ K+ ∧ j > i) ∨ (i, j ∈ K− ∧ j < i)
U (0.01, 0.05) if (i, j ∈ K+ ∧ j < i) ∨ (i, j ∈ K− ∧ j > i)
U (0.001, 0.02) if i = j̄
U (0.001, 0.005) else
where U (a, b) is the uniform distribution with lower bound a and upper bound b. Rows of A∗
are then normalized to sum up to 1. An example of a simulated transition matrix is shown
Figure 4. To get realistic simulations, emission distributions were simulated from fitted emissions
of the yeast data set, using five non-strand-specific (ChIP) and two strand-specific (expression)
observation tracks.
We did 100 simulation runs. The state numbers were randomly chosen from U (5, 10) in each single
run and sequences with 15000 observations were generated. Model parameters were initialized as
follows
aij = 1/K
πi = 1/K
µi = µtrue + εi , εi ∼ N (0, 0.01)
Σi = 0.01 · E
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where E is the identity matrix. In each simulation run, models were learned on simulated ob-
servation sequences of length 1,000 (respectively 10,000). The fitted values âij showed a good
agreement with the true parameter values aij , even when the model was only trained on 1000
observations (Figure 4). The state annotation recovered a median of 97% respectively 99.5% of
the true underlying hidden states on sequences not used for training, when the model was trained
on an observation sequence of length 1,000 respectively 10,000 (Figure 4).
10 Analysis of directed genomic states in yeast
The following describes analyses that were carried out to annotate and analyze directed genomic
states in yeast using bdHMMs. The results are presented in section 14.
10.1 Experimental data and preprocessing
The experimental yeast dataset was compiled from public data [4,31,33,36,54]. All measurements
were done using the high density custom-made Affymetrix tiling array (PN 520055) which tiles
each strand of genomic DNA in yeast at a resolution of 8bp. ChIP experiments were normalized
using the R/Bioconductor [156,161] package Starr [168] as previously described [169]. Expression
data was normalized using the tilingArray package [170].
The human chromatin modification dataset was downloaded from the supplemental website of
[150], where they provided the preprocessed sequencing and binary data.
10.2 Clustering of state sequences
A set of valid coding genes was selected from initally 6,603 ORFs from SGD. 5,088 of them had
an annotation of transcript boundaries provided by [4]. Next, we selected transcripts where the
TSS was located upstream and the pA site downstream of the coding region, yielding 4,687 genes.
Then, state paths were extracted from the bdHMM annotation with a ±250 bp flanking region.
We further selected transcripts where more than 80% of positions were annotated to the proper
strand. This resulted in 4,263 genes, which were rescaled to a common length. Pairwise Hamming
distances were computed and the sequences were hierarchically clustered. The dendrogram was
cut off to yield 55 clusters. Gene-set enrichment analysis was carried out using mgsa [171, 172].
A GO group was considered active if the posterior probability was > 0.5.
10.3 Targeted identification of genomic features
Let S+ = {PE1+, PE2+, eE1+, eE2+, eE3+,mE1+,mE2+,mE3+,mE4+,mE5+, lE1+, lE2+lE3+, T1+}
be a set containing all forward states, excluding state P/T2+ . Let S− be defined likewise for re-
verse states. We defined regular expressions ((S+|T2)+|(S−|T2)+) and (S−)+(P/T1|P2|P1)+(S+)+
to search for transcripts and bidirectional promoters throughout the yeast genome. Transcripts
were constrained to have a minimal length of 80bp. We uniquely assigned the 6,068 predictions
to previously annotated transcripts [4], using the best reciprocal hit with respect to transcript
boundary distance. This yielded 4,186 uniquely assigned transcript predictions. Estimated cu-
mulative distribution functions were computed to assess the accuracy of the predictions. The
predictions of bidirectional promoters were not subsequently filtered. The newly identified tran-
scription units were assigned a class (coding, SUT or CUT) using the SGD ORF annotation [173]
and expression data from [4].
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Figure 4: Simulations show good performance of bdHMM parameter inference. 100 simulations (15000
observations in each round) were carried out to assess performance of recovery of bdHMM transitions
when the model was learned on 1000 (A) or 10000 (B) observations. (C) shows the respective recovery of
state annotation on the training data and data not used for learning (test data). (D) shows an example
of simulated bdHMM transitions.
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10.4 De novo motif discovery
DNA sequences were extracted for each genomic state. To increase sensitivity of the motif search
we excluded very long and very short sequences (min. length: 150bp, max length: 90% quantile
of sequence lengths for a state). Motif search was carried out using XXmotif [174], which uses
a negative sequence set to calculate p-values for motif enrichment. The choice of this negative
set can be crucial, since it corrects for general sequence features. We chose as negative sets,
upstream sequences starting at -50bp relative to the current genomic state. A sequence motif
was considered to be enriched if it had an e-value < 10−6 and occured in at least 5% of all
sequences. The TOMTOM software [175] was used to search databases for similar known motifs.
Functional descriptions of transcription factors were obtained from SGD [173].
11 Analysis of chromatin modifications in human CD4 T-cells
The following describes analyses that were carried out to annotate and analyze directed chromatin
states in human CD4 T-cells. The results are presented in section 14.
11.1 Fitting a standard HMM and a bdHMM to human chromatin modifi-
cations
We fitted a bdHMM to binary chromatin modification data from Ernst and Kellis [150] which
previously had been analysed by the ChromHMM algorithm. The Bernoulli emission probabilities
learned by ChromHMM were fixed and only transitions were updated during the learning of
the bdHMM. This was done to ensure that the improvements over ChromHMM are only due
to the altered modeling of the transitions. First, an HMM transition matrix was fitted using
ChromHMM transitions (51 states) as initialization, whereby 10−3 was added to each transition
probability. The bdHMM transition matrix was generated by inflating the transition matrix
learned by the standard HMM to a 102×102 matrix. Thus our model initially did not contain any
undirected states. A flag sequence was generated from annotated GENCODE [104] transcribed
units (version 3c) to set directionality constraints at actively transcribed regions. The 39,447
GENCODE annotations were filtered for non-overlapping transcripts with a minimal length of
1000 bp and minimal distance of 5,000 bp to neighbouring transcripts on both strands (6,385).
This set was filtered for expressed transcripts showing a median Pol II signal greater than the
25% quantile. This yielded 1,637 actively transcribed regions, which were used to generate a flag
sequence, covering approximately 6% of genomic positions. After EM-learning of the bdHMM
transitions, the most likely state path was calculated using Viterbi decoding. Running time for
bdHMM learning was 22h using the multiprocessing version of STAN with 30 cores.
11.2 Comparison of bdHMM and ChromHMM
The bdHMM annotation (i.e. the Viterbi path) was compared to the ChromHMM annotation.
The comparison was carried out by identifying bdHMM states with their ChromHMM coun-
terpart having identical emission distributions. This means that conjugate forward and reverse
bdHMM states are mapped to the same ChromHMM state. 83% of state annotations matched
between bdHMM and ChromHMM. To account for differences in the implementation and model
fitting (ChromHMM for instance uses a non-deterministic version of the online EM while our
implementation uses the standard EM algorithm) of ChromHMM and bdHMM, we also re-fitted
the transitions of a standard HMM using the STAN package, which was initialized with the
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parameters reported by Ernst and Kellis [150], keeping the emission distributions fixed. The
agreement between the bdHMM and re-fitted HMM annotation was 97%, showing that bdHMMs
essentially add directionality to chromatin states.
12 Chromatin state annotation and benchmark of GenoSTAN in
127 ENCODE cell types and tissues
The following describes analyses that were carried out to annotate and analyse chromatin states in
127 human cell types and tissues from the ENCODE [93] and Roadmap Epigenomics projects [110]
using GenoSTAN. The results are presented in section 15.
12.1 Data preprocessing
Three data sets, benchmark I, II and III (Figure 13B), where compiled from the ENCODE and
Roadmap Epigenomics projects [93, 110]. Benchmark I (K562 ENCODE) sequencing data was
mapped to the hg20/hg38 (GRCh38) genome assembly (Human Genome Reference Consortium)
using Bowtie 2.1.0 [176]. Samtools [177] was used to quality filter SAM files, whereby alignments
with MAPQ smaller than 7 (-q 7) were skipped. To estimate midpoint positions of the ChIP-Seq
fragments, the (single end) reads were shifted in the appropriate direction by half the average
fragment length as estimated by strand coverage cross-correlation using the R/Bioconductor
package chipseq [156]. Next, ChIP-Seq tracks were summarized by the number of fragment
midpoints in consecutive bins of 200 bp width. The data for the 127 ENCODE and Roadmap
Epigenomics cell types (benchmark II and III) was downloaded as preprocessed tagAlign files from
the Roadmap Epigenomics supplementary website [110]. Fragment length was again estimated
using the R/Bioconductor package chipseq and reads were shifted by the fragment half size to the
average fragment midpoint [156]. The genome was partitioned into 200bp bins and reads were
counted within each bin.
12.2 Model fitting of GenoSTAN
GenoSTAN was fitted on the complete data of benchmark data set I. The signal used for GenoS-
TAN model training on Benchmark data set II and III was extracted from ENCODE pilot regions
(1% of the human genome analyzed in the ENCODE pilot phase [99]) for each cell type, which
together covered 20% and 127% of the human genome. The GenoSTAN-nb-20 model was learned
in one day, the GenoSTAN-Poilog-20 model in two days using 10 cores. Model learning on Bench-
mark set II using 10 cores took three (GenoSTAN-nb-127) and six days (GenoSTAN-Poilog-127).
Precomputed library size factors were used to correct for variation in read coverage.
12.3 Model fitting of ChromHMM, Segway and EpicSeg
The data was binarized as described in [150] and ChromHMM was fitted with default parameters.
Before applying Segway, the data was transformed using the hyperbolic sine function [101] and a
runing mean over a 1kb sliding window was computed to smooth the data. Segway was fitted on
ENCODE pilot regions using a 200bp resolution. EpicSeg was fitted on the untransformed count
data with default parameters.
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12.4 Processing of chromatin state annotations and external data
All state annotations and external data were lifted to the hg20/hg38 (GRCh38) genome assembly
using the liftOver function from the R/Bioconductor package rtracklayer [178]. Overlap of state
annotations with external data was calculated with GenomicRanges [179].
12.5 Computation of area under curve
AUC values were calculated on benchmark I for GenoSTAN, ChromHMM, Segway and EpicSeg.
To this end, a segmentation was transformed into a binary classifier and evaluated as follows.
Each 200bp bin in the genome overlapping with HOT (TSS) regions was considered as ’true
condition’, the rest as ’false’. For each state S the precision for recalling HOT (TSS) regions was
calculated as the fraction of all segments annotated with S that overlapped with a HOT (TSS)
region. States were then sorted by decreasing precision. The rank of each state was used as score
in the prediction of HOT (TSS) regions on each 200bp bin in the genome, which was then used
to calculate AUC values.
12.6 Analysis of transcription factor (co-)binding
TF enrichment in chromatin states was calculated as described earlier [180]. Let TFnt be the total
number of nucleotides in the binding sites (peaks) of a TF and TFnts the number of nucleotides
in the binding sites that overlap with state s. Further let snt be the total number of nucleotides
in the genome covered by state s and let l be the length of the genome. TF enrichment is then
calculated as TF
nt
s /TF
nt
snt/l . For each TF, enrichments were normalized to sum up to 1 across all 18
chromatin states (GenoSTAN-Poilog-K562). The co-binding rate was calculated as the frequency
of binding sites of two TFs that co-occur in a chromatin state divided by the number of all binding
sites of the two TFs (Jaccard index).
12.7 Tissue-specific enrichment of disease- and complex trait-associated vari-
ants in regulatory regions
The GWAS catalog was obtained from the gwascat package from Bioconductor [156, 181]. Sta-
tistical testing was carried out in a similar manner as described in [110]. The enrichment of
SNPs from individual genome-wide association studies was calculated for traits with at least 20
variants. SNPs for each trait were overlapped with promoter and enhancer regions and tested
against the rest of the GWAS catalogue as background using Fisher’s exact test. P-values were
adjusted for multiple testing using the Benjamini-Hochberg correction. In order to calculate the
recall and frequency of SNPs, promoter and enhancer states were randomly sampled until a ge-
nomic coverage of 2% for enhancers and 1% of promoters was reached. This was done to control
for the fact that methods can differ among each other regarding the length of the promoters and
enhancers they predict. This procedure was repeated 100 times enabling the calculation of 95%
confidence intervals.
12.8 Availability of GenoSTAN and chromatin state annotations
GenoSTAN is part of the R/Bioconductor package STAN [113]. The combined promoter and
enhancer annotation and all chromatin state annotations for benchmark I, II and III can be
downloaded from http://i12g-gagneurweb.in.tum.de/public/paper/GenoSTAN.
36
13 Mapping the human transient transcriptome from TT-Seq data
The following describes analyses that were carried out to annotate transcription units that were
derived from transient transcriptome sequencing (TT-Seq). Additional experimental protocols
(carried out by Margaux Michel) and statistical methods for calculation of RNA half lives and
synthesis rates (carried out by Björn Schwalb) can be found in Appendix section 18. The results
are presented in section 16.
13.1 Transcription Unit (TU) annotation
Genome-wide coverage was calculated from TT-Seq fragment midpoints in consecutive 200 bp
bins throughout the genome. Binning reduced the number of uncovered positions within expressed
transcripts and increased the sensitivity for detection of lowly synthesized transcripts. A two-
state hidden Markov model with a Poisson-lognormal emission distributions was learned using
GenoSTAN in order to segment the genome into “transcribed” and “untranscribed” states, which
yielded an initial prediction of 86,676 TUs. In order to filter out spurious predictions, we defined
a threshold for minimal expression (RPK) based on TUs overlapping with annotated GRO-cap
TSSs [13]. The threshold was optimized based on the Jaccard-Index, which resulted in 39,811 TUs
with a minimal RPK of 15.5 (Figure 5A). To further filter these, we required each TU to overlap
with an annotated GRO-cap TSS, an annotated GENCODE transcript (version 22, [104]), or that
the TSS of the TU overlaps with a prediction of an active promoter state (PromW.5 or Prom.11
from GenoSTAN-Poilog-K562, see Methods section 12, Figure 14) or enhancer state (EnhW.2 or
Enh.15 from GenoSTAN-Poilog-K562, see Methods section 12, Figure 14) from our chromatin
state segmentation. 21,874 TUs were supported by at least one of these external data sets (Figure
5B). Subsequently, TU start and end sites were refined to nucleotide precision by finding borders
of abrupt coverage increase or decrease between two consecutive segments in the two 200 bp bins
located around the initially assigned start and stop sites via fitting a piecewise constant curve to
the coverage profiles (whole fragments) for both replicates using the segmentation method from
the R/Bioconductor package tilingArray [170].
13.2 Transcript sorting
We sorted each TU into one of the following seven classes: enhancer RNA (eRNA), short in-
tergenic non-coding RNA (sincRNA), antisense RNA (asRNA), convergent RNA (conRNA), up-
stream antisense RNA (uaRNA), long intergenic non-coding RNA (lincRNA) and messenger RNA
(mRNA). First, TUs reciprocally overlapping by at least 50% in the same strand a GENCODE
annotation (version 22, [104]) were classified as the respective GENCODE transcript type (e.g.
mRNAs and lincRNAs). Next, TUs located on the opposite strand of either a mRNA or lincRNA
were classified as asRNA – if the TSS was located > 1 kb downstream of the sense TSS – as
uaRNA if its TSS was located < 1 kb upstream of the sense TSS – and as conRNA if its TSS
was located < 1 kb downstream of the TSS. Each of the remaining TUs did not overlap with
GENCODE annotation and were classified as eRNA – if its TSS fell into an enhancer state –
or as sincRNA – if its TSS fell into a promoter states. This resulted in 19,219 non-ambiguously
classified RNAs on which the rest of the analysis was focused.
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Figure 5: Accurate annotation of transcripts based on TT-Seq data using GenoSTAN (A) Jaccard index
(overlap with GRO-cap TSSs) for different choices of thresholds (RPK, x-axis). (B) Venn diagram showing
the overlap of the predicted and filtered 21,874 TUs with external data sets.
13.3 RNA structure and U1 motifs
The first 1000 nt from the RNA 5’-end (TSS) of each transcript was divided into 100 nt bins,
where successive bins were shifted by 50 nt. The free folding energy of each of these bins was
calculated using RNAfold from the ViennaRNA package [182] and the bin with the minimal free
energy was selected for plotting as a measure for the most stable local structure within the region.
Predicted structured RNAs in the human genome were selected from [183], overlapped with the
TT-Seq transcript annotation and half-lives were plotted (Appendix Figure A11B, C). To analyze
RNAs for the occurrence of U1 motifs, the 5’-most 1000 nt of each transcript were screened for
occurrences of the consensus sequence of the U1 binding site (GGUAAG) and for those of the
5’-splice site GGUGAG and GUGAGU. Transcripts were then divided into ‘zero’ or ‘one or more’
occurrences and transcript lengths and half-lives were plotted.
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Part III
Results & Discussion
14 Annotation of genomics data using bidirectional hidden Markov
models unveils variations in Pol II transcription cycle
The results presented in this section were previously published in [113]. For detailed author con-
tributions see page ix.
An important question in molecular biology is how the occupancy of a genomic position with
protein factors relates to the composition of genome-associated protein complexes at this posi-
tion. This question is of high relevance to fundamental genome-associated processes such as DNA
replication, transcription and repair because these generally involve the formation of functional
multi-protein complexes that undergo transitions in their protein composition along the genome.
For example, during transcription, RNA polymerase (Pol) II progresses through the initiation,
elongation, and termination phases, which are characterized by the presence of distinct Pol II-
associated proteins and various post-translational modifications of Pol II and histones. Analysis
of genome-wide occupancy maps of Pol II-associated factors obtained by chromatin immunopre-
cipitation (ChIP) in yeast indicates the presence of distinct protein complexes for the initiation,
elongation, and termination of transcription, which are formed during a universally conserved
mRNA transcription cycle [33,78,184]. These conclusions were deduced from metagene analysis,
i.e., the averaging of occupancy profiles over a pre-selected set of representative genes. In the
present work, we check this hypothesis on the single-gene level.
To systematically investigate occupancy profiles in an unbiased, position-specific manner, hidden
Markov models [112] were used to describe longitudinal observations as a sequence of discrete
states (here: genomic states, which model the genome-associated complexes). HMMs have been
used to infer chromatin states and annotate enhancers, promoters, transcribed and quiescent
regions in the genome of human [101,102,103,147,148,150,151] and fly [185,186]. For instance,
Ernst and Kellis [150] infer promoter and transcribed chromatin states in human T-cells, which
occur in a typical order upstream and downstream of annotated transcription start sites (TSSs).
However, these state-of-the-art HMM approaches infer genomic states in a non-strand-specific
(or undirected) manner. For example, they cannot decide whether a bona fide “TSS-upstream”
state generally precedes or follows a bona fide “TSS-downstream” state. Directionality informa-
tion needs to be included in a post-processing step. Moreover, these models lack a sound way
to integrate strand-specific (e.g. expression) with non-strand-specific (e.g. ChIP) data, which is
indispensable to appropriately characterize strand-specific genomic processes.
To address these issues, we develop the theory of bidirectional hidden Markov models (bdHMMs),
a novel probabilistic model that annotates directed states from non-strand-specific data (such as
ChIP), and optionally strand-specific data (such as RNA expression). We introduce the concept
of ‘directed genomic states’, which encode directionality information and thus provide a more
realistic model of the underlying genome-associated complexes and their transitions. We present
a very efficient algorithm for the learning of the bdHMM, available with the R/Bioconductor
package STAN (http://www.bioconductor.org/packages/devel/bioc/html/STAN.html).
The broad applicability of our method is demonstrated on two entirely different data sets, namely
on a tiling array transcription factor dataset in yeast and a deep-sequencing histone dataset in
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human. We show that bdHMM produces more accurate genome annotations than standard
HMM. Our bdHMM analysis of previously defined chromatin states in human T-cells [150] de
novo identifies directed chromatin state patterns and provides an improved annotation of the
human ‘histone code’. Application of the bdHHM method to a set of 22 genomic profiles in
the S. cerevisiae finds new transcription units and DNA sequence motifs, and unveils so far un-
known variations in the Pol II transcription cycle. The yeast and human data sets, their state
annotation, and bdHMMs which generated them, are available from the supplementary website
www.treschgroup.de/STAN.html. Using essentially the same set of parameters, the bdHMM is
as easy to learn as standard HMM while extracting more information. We therefore anticipate
bdHMM to replace standard HMM in a wide range of genomics analyses.
14.1 Annotation of directed genomic states using bdHMMs
Standard and bidirectional HMMs are best understood with the help of a simulated dataset. A
precise definition of the HMM and a bdHMM is given in the Methods (section 8 and 9). The
example in Figure 6 considers a part of the genome where transcription occurs as a sequence of
three different genomic segments. The transcribed regions split into segments of early (E) and
late (L) transcription activity, and they are flanked by untranscribed (U) segments.
The order of the three segments U, E, and L along the genome depends on the orientation of the
respective gene (Figure 6A, grey arrows). ChIP measurements o0, o1, ..., oT for a single protein at
genomic positions t = 0, 1, ..., T were simulated with low (U), medium (E) and high (L) average
occupancy in the different segments. Note that these ChIP signals do not contain strand-specific
information. An HMM defines a probability distribution on a sequence of observations o0, ..., oT .
It assumes that each observation ot is emitted by a corresponding (unobserved) state variable
st which can assume values from a finite set of hidden states. The value of st determines the
probability of observing ot, Pr(ot | st). The hidden variables form a first order Markov chain,
which means that the probability for observing st depends only on st−1, the transition probability
Pr(st | st−1). After the learning of these probabilities, the HMM outputs the so-called Viterbi
path, which is the most likely state sequence s0, s1, ..., sT that generated the observations. In our
example, the Viterbi path provides a genome annotation.
A standard HMM with 3 hidden states can distinguish the three protein occupancy levels; the
three states correspond to the three genomic segments (Figure 6B) and are therefore also called
U, E, and L. However, the transition probabilities in the standard HMM are symmetric because
the number of observed transitions between successive segments, say E to L, in the forward di-
rection equals the number of transitions in the reverse direction, L to E. Hence, standard HMMs
are neither able to capture the strand-specificity of transcription (i.e. the two different directions
of transcription along the genome) nor do they infer biologically meaningful transitions along the
genome as they occur during transcription.
In order to infer directed transitions and directed genomic states, bdHMMs have ’twin states’, one
for each strand and genomic state. For instance, the early state E is split up into the twin states
E+ and E−. Twin states are coupled by two symmetry conditions. First, twin states are required
to have identical emission probabilities, i.e., in our example Pr (ot|st = E+) = Pr (ot|st = E−),
where ot is the observed data and st is the hidden (transcription) state at position t. Second,
twin states satisfy transition symmetry, a novel generalization of reversible Markov chains (see
Methods section 9 for details), which requires that state transitions are invariant under reversal
of time and direction, i.e. Pr (st = L+|st−1 = E+) = Pr (st−1 = L−|st = E−). By splitting up E
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Figure 6: Principle of bidirectional HMM (bdHMM). (A) Simulated occupancy signal (1st track from
the top) for a putative factor with a low level (centered at 0) in untranscribed regions (state U), an
intermediate level in the 5’ part of genes (state E), and a high level in the 3’ part of genes (state L).
Arrows (2nd track) depict boundaries and orientation of transcription. Unlike standard HMM (3rd track)
bdHMM (4th track) infers strands (+ or -) to expressed states (E, L). (B) HMM transition graph. Because
orientation of transcription is not modeled by standard HMM, the spurious reverse transitions (E ⇒ U ,
L⇒ E, and U ⇒ L) are as likely as the correctly oriented transitions (U ⇒ E, E ⇒ L, and L⇒ U). (C)
bdHMM transition graph. In contrast to HMM, bdHMM, which has explicit strand-specific expressed
states (E+/E− and L+/L−), allows inferring only the correctly oriented transitions.
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respectively L into E+ and E− (respectively L+ and L−), the bdHMM learns the transitions for
each direction separately, but not independently of each other. In our example, this results in the
bdHMM transition probabilities Pr (st = L+|st−1 = E+) > 0, and Pr (st = L−|st−1 = E−) = 0,
as opposed to Pr (st = L|st−1 = E) > 0 and Pr (st = E|st−1 = L) > 0 in the HMM (Figure 6B,C).
These two conditions enable the recovery of the direction of genomic states (Figure 6A). Although
the formal number of states doubles, the effective number of parameters does not increase due to
the bdHMM constraints.
Parameters are inferred using a constrained Baum-Welch algorithm, the validity of which was
assessed by simulations showing that model parameters and states were recovered with high accu-
racy, even when only few training data was used (Methods section 9, Supplementary Figure 8 and
9 in [113]). The bdHMM is implemented in the R package STAN (Genomic STate ANnotation),
which is freely available on Bioconductor (http://www.bioconductor.org/).
14.2 Genomic state annotation results in a global, strand-specific transcrip-
tion map
We applied the bdHMM to ChIP data in S. cerevisiae, where high-resolution data sets for dozens
of proteins of the transcription machinery are available. We compiled genome-wide ChIP-chip
experiments for transcription initiation factors (TFIIB, Kin28), elongation factors (Spt5, Spn1,
Bur1, Spt16, Ctk1, Paf1), termination factors (Pcf11, Rna15, Nrd1), Pol II and various modifi-
cations of its C-terminal domain (CTD) (Tyr1P, Ser2P, Ser5P, Ser7P) and nucleosomes . The
data set was complemented by strand-specific mRNA expression data [4] (Figure 7).
The number of bdHMM states needed to be specified in advance. Bearing in mind that our
states should distinguish biologically different genomic states, classical model selection crite-
ria (BIC, AIC, MDL) are not useful. Those criteria balance the number of parameters/states
against the precision of the data fit. Since our data is very rich, they suggest a very high number
of states, which cannot be interpreted. This issue has been reported repeatedly in association
with HMMs [101,102,150] for integrative analysis of ChIP data. We tried several state numbers
(data not shown) and found that 20 states yielded an appropriate trade-off between model com-
plexity and biological interpretability. Simulations from the inferred bdHMM recovered model
parameters with high accuracy and further confirmed the validity and stability of the model
(Supplementary Figure 9 in [113]).
The genome-wide state annotation was derived as the most likely state path (Viterbi decoding,
Figure 7), which partitioned the 12 Mb yeast genome into 48,507 directed and 10,760 undirected
state segments with distinct bdHMM states. This yields a strand-specific partitioning of the yeast
genome into segments of directed genomic states. Alternative to Viterbi decoding, posterior de-
coding or mixed approaches (Posterior-Viterbi decoding, [187]) could be used. Generally, Viterbi
decoding is less subject to state flipping compared to posterior decoding. However, we did not
see relevant differences between both approaches in this application (97% of genomic positions
are annotated with the same state when comparing Viterbi and posterior decoded state paths).
14.3 bdHMM state annotation recovers annotated genomic features with
high accuracy
In principle, the strand-specific expression of this dataset could also be used with standard HMMs
to learn directed states. However, fitting a standard HMM did not recognize directed genomic
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Figure 7: De novo annotation of directed genomic states from genome-wide transcription data in yeast
using bdHMM. Input for the bdHMM are, from top to bottom: strand-specific wild-type RNA levels,
occupancy maps of nucleosomes, 3 termination factors, 6 elongation factors, 3 capping factors, 2 initiation
factors, 4 CTD modifcations, and 1 core Pol II member (Rpb3). Inferred directed genomic states are
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centered on the axis. Previous transcriptome annotation is shown in the 2nd track from the bottom.
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states. In particular - since the HMM is learned without symmetry constraints for twin states
- there is no obvious pairing between the forward (+) and the reverse (-) states, demonstrating
the need for bdHMM (Supplementary Figure 1 in [113]).
In order to re-annotate transcription throughout the yeast genome and compare the performance
of bdHMM and HMM, we applied a regular expression (RegEx) approach (Figure 8A), to predict
transcribed units as continuous stretches of directed transcribed states with a minimal length of
80 bp on both strands from the bdHMM and HMM annotation. Matching predicted transcript
boundaries to previously published ones [4], 4186 (82%) of all annotated protein-coding transcripts
were recovered from the bdHMM predictions, 11% more than the HMM predicts using the same
criteria (3639 transcripts) (best reciprocal hits, Methods section 10). Moreover, the predicted
transcription start sites (TSS) were consitently closer to the annotated ones (Figure 8D). In
particular, 60% of the preditcted TSSs by the bdHMM were within 50 bp, whereas the best 60%
of the HMM TSS predictions were within 100bp of the published ones. Accuracy of pA site
prediction was lower, but comparable between bdHMM and HMM, where approximatley 60% of
the predicted pA sites were within 100bp of the annotated ones for both methods. Moreover, 32
novel transcripts were predicted from the bdHMM annotation (4 overlapping a coding region, 28
non-coding, Figure 8C, Methods section 10), which is of particular significance because the S.
cerevisiae transcriptome has been thoroughly studied and annotated.
As another illustration of genomic features that can be extracted from a bdHMM annotation,
we searched for bidirectional promoters using a RegEx consisting of a promoter state flanked by
an upstream transcript on the Crick strand and a downstream transcript on the Watson strand
(Figure 8A,B). We detected 1,076 bidirectional promoters in yeast, which agrees well with a
previous estimate of 1,049 bidirectional promoters [4]. Altogether, these results demonstrate the
high accuracy of the bdHMM for genome annotation and its advance over the standard HMM.
14.4 Transcription cycle phases have a substructure
To understand how the 20 bdHMM states relate to phases of the transcription cycle, we analyzed
their average frequencies along annotated, transcribed genes (Figure 9B, Methods section 10).
The states showing a single frequency peak (18 out of 20 states) were grouped into six transcription
phases, according to the location of their peak on the average gene: Promoter (P, 2 states),
Promoter Escape (PE, 2 states), early Elongation (eE, 3 states), mid Elongation (mE, 5 states),
late Elongation (lE, 3 states), and Termination (T, 2 states). Two states showed two peaks in
frequency, in each case with one peak upstream of the transcription start site and one peak around
the polyadenylation (pA) site. We interpreted these two states as mixed promoter and termination
states and labeled them accordingly P/T1 and P/T2 (Figure 9A,B). Hence, although overlapping
transcription is not explicitly modeled by bdHMMs, this phenomenon could be captured by
specific states.
The mean factor occupancy defining a particular state is indicative of the composition of the
transcription complex and its activity (Figure 9A). Indeed we found that the enrichment or
depletion of protein factors in each state was in accordance with their known roles in transcription
(Figure 9A). For instance, the initiation factors TFIIB and Kin28 were enriched in promoter and
promoter escape states (P2, PE1, PE2), and were depleted in states of other transcription phases
(Figure 9A,B). States related to the same transcription phase often peaked at successive genomic
positions. For instance, the mid-elongation phase comprises successive states mE1-mE5 (Figure
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Figure 8: Genomic state annotation predicts bidirectional promoters and (novel) transcripts. (A) The
genomic state annotation (viterbi path) was searched with Regular Expressions (RegEx) defining bidi-
rectional promoters (right) and transcripts (bottom). (B) Nucleosome binding patterns centered at 1,076
identifed bidirectional promoters found with the RegEx. Each line in the heatmap corresponds to one
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detectable expression but was too low for the criterias used by [4] (D) Estimated cumulative probability
of TSS and pA site predictions show higher accuracy of bdHMM in recovering TSSs. pA site prediction
has similar accuracy for both models.
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Figure 9: Roles of directed genomic states in the transcription cycle. (A) Mean ChIP enrichment of
factors (horizontal axis) indicates the composition of the transcription machinery in each state (vertical
axis). Factors were ordered by hierarchical clustering and states were ordered by position of their most
frequent occurrence along the average gene. (B) Each state was assigned to a phase in the transcription
cycle by investigating the frequency (y-axis) of each state at an average transcript. This spatial state
distribution was calculated from the genomic sate sequences (viterbi paths) of 4,362 genes. (C) The
flux diagram shows probabilities of state transitions calculated from the viterbi paths. Branches mark
alternative successions of states at individual genes and thus reveal extensive variation in the transcription
cycle as it is modeled by the genomic states. Each node (state) is positioned according to the most frequent
position on a metagene. The diagram contains at least one incoming and one outgoing transition for each
state as well as transitions observed with a frequency > 0.01 on the metagene.
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9B, C) that were characterized by a gradual decrease in the occupancy of initiation factors,
capping-related factors, and Nrd1 (Figure 9A).
Overall, these results show that unsupervised bdHMM analysis can define meaningful genomic
states that reflect phases of transcription at every single gene.
14.5 The transcription cycle shows gene-specific variation
Our bdHMM annotation did not only recapitulate known events during transcription, it also
provided unexpected, new insights. For example, the flux diagram (Figure 9C, showing the
most likely transitions between successive states) indicated variability within the transcription
cycle. We found different states at the same position within genes that may reflect alternative
functional transcription complexes (Promoter: P1, P2, P/T1, or P/T2; Promoter escape: PE1
or PE2; Figure 9A,B). These alternative states are located within different branches of the flux
diagram (Figure 9C). A pronounced bifurcation occurs at the transition from P2 to promoter
escape, entering either highly productive (PE2) or weak transcription (PE1). These two branches
of the transcription cycle converge again during late elongation (lE2, lE3) or termination (T1).
Hence, the analysis of state frequency distributions and transition diagrams suggests gene-specific
variation of the transcription cycle.
For a systematic investigation of gene-specific variation during the transcription cycle, we clus-
tered genes based on their annotated state path. To that end, the state paths of 4,263 genes were
rescaled to a common length and clustered into 55 groups according to their Hamming distance
(Figure 10A,B, Methods section 10). The obtained gene clusters show distinct patterns of protein
occupancies suggesting mechanistic differences in transcription (Figure 10, Supplementary Figure
2 in [113] and below). Moreover, the gene clusters differed by gene length, expression level, and
genomic context (e.g. termination overlaps with a neighboring downstream promoters or bidirec-
tionality of promoters). Gene set enrichment analysis showed that clusters also corresponded to
distinct functional gene groups (Supplementary Table 1 in [113]). The functional categories range
from house-keeping (e.g. cluster 14, 38), cell cycle (e.g. cluster 17) to stress response (e.g. cluster
39). For instance, the high expression of cluster 38 and 14 is in accordance with their associated
functions including ribosome biogenesis, positive regulation of transcription, translation or nu-
cleosome assembly. More strikingly, we found the DNA binding motif of SFP1 - a regulator of
ribosomal protein and ribosome biogenesis genes - to be enriched in promoter state P/T1 (which
is a frequent promoter state of cluster 14 and 38 genes, Supplementary Figure 4 in [113]). In
contrast, stress- and autophagy-related genes in cluster 39 show very low expression and protein
binding (Supplementary Figure 2B in [113]). Altogether, this suggests that different transcription
cycles as they are modeled by the bdHMM correspond to different co-regulated gene sets.
Cluster 14, which contains 694 genes (Figure 10B,C, Supplementary Figure 2B in [113]), shows
a transcription cycle most similar to the canonical one proposed previously [33]. In this cluster,
the promoter escape state PE2 was characterized by peak occupancy of the Pol II core subunit
Rpb3 between 100 and 200 bp downstream of the TSS, and phosphorylation of the CTD serine 2
residue reaches maximum levels between 600 and 1,000 bp (Figure 10D), as observed in previous
metagene analysis. The cycle ends with the canonical termination state T1, which is characterized
by the presence of elongation factors Spn1, Paf1, Ctk1, Bur1, Spt16, Spt5, and termination factors
Pcf11 and Rna15 (Figure 9A).
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Figure 10: Clustering of state paths reveals gene-specific variations in the transcription cycle. (A)
Genomic state sequences of 4,632 genes were clustered into 55 groups (left, only clusters containing at
least 20 genes are labeled). Each line corresponds to the state sequence of a single gene. States are colored
as shown in the legend. (B) Clusters exhibit distinct state frequency distributions and transition patterns
(shown as schematic flux diagrams on top of panels). Cluster 14 shows a transcription cycle closest to the
canonical one proposed by [33]. Genomic state sequences of cluster 32 and 38 differ from the canonical
one, indicating variations in the transcription cycle. (C) Cluster 14 and 32 exhibit distinct recruitment
of factors to genes. PolII subunit Rpb3, Nrd1, Spt5 and Spt16 binding is very similar in the beginning of
genes, but decreases much stronger in cluster 32 throughout the transcripts. Ctk1 and Paf1 are depleted
at cluster 32, but not at cluster 14 genes. (D) Cluster 14 shows the canonical Pol II (Rpb3) peak in the
5’ region of genes, but Pol II reaches a stable, high level downstream of the TSS in cluster 38. This may
suggest a lack of the mechanism for Pol II peaking observed in cluster 14. The steep increase of Serine 2
phophorylation in cluster 38 might indicate that productive elongation is reached earlier at those genes.
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14.6 Evidence for regulated promoter escape
We next analyzed clusters with variations compared to the canonical transcription cycle. Clus-
ter 32 (43 genes) differs from the canonical cluster 14 in the transition from promoter escape
to elongation. State frequency and gene-averaged ChIP signals suggest that transcription is at-
tenuated after promoter escape in cluster 32 (Figure 10B,C). In this cluster, a strong promoter
escape (PE2) is followed by the weak elongation state eE3, which is characterized by low levels
of Pol II and elongation factors (Figure 9B,C, Figure 10C). Moreover, elongation factors Ctk1
and Paf1 appear to be absent from those genes (Figure 10C, Supplementary Figure 2C in [113]).
In contrast, cluster 14 exhibits similarly strong promoter escape yet transitions into the highly
productive elongation states eE2 and mE1, which are characterized by high occupancies of all
measured elongation factors (Figure 9B,C). This comparison supports the existence of a regu-
latory checkpoint for transcription elongation after promoter escape. This is likely related to
transcription attenuation with the help of the early termination factor Nrd1, since cluster 32
genes show significant upregulation after Nrd1 depletion from the nucleus [26] (Figure 10C, Sup-
plementary Figure 3 in [113]). The individual occupancy profiles (Figure 10C, Supplementary
Figure 2C in [113]) indicate that this checkpoint separates the binding events of Spt5, Spn1,
Bur1, Spt16 from the binding of Ctk1 and Paf1. Thus, it appears that attenuated genes recruit
early elongation factors including Spt5 and Spt16, but not the later factors Paf1 and Ctk1.
14.7 Evidence for distinct transcription mechanisms for highly expressed
genes
Cluster 38 differs strikingly from the canonical transcription cycle during early elongation and
termination (Figure 10B, Supplementary Figure 2D in [113], 147 genes enriched for genes involved
in translation, Supplementary Table 1 in [113], Methods section 10). Cluster 38 is characterized
by the high occupancy promoter state P/T1 (Figure 9A) and by the early elongation state eE1
(for 58% of all cluster 38 genes, and in turn 48% of genes with eE1 state are in cluster 38).
During early elongation, serine 2 phosphorylation levels increase more steeply than in cluster 14,
indicating that productive elongation is reached earlier at those genes (Figure 10D). Moreover, Pol
II does not exhibit the typical occupancy peak 150 bp downstream of the TSS but immediately
reaches a stable high level (Figure 10D). This profile could be the consequence of a lower drop-off
rate at this position [33], a more constant elongation rate along the gene, or a high and uniform
coverage by elongating polymerases. Specifically to cluster 38, a sharp decrease of the occupancy
of essentially all factors is observed well-positioned at the stop codon (Supplementary Figure
2D in [113]). The data indicates that most factors (Cbp20, Nrd1, Ctk1, Paf1, S5P, S7P, Spt16
and Bur1) are then released, as their occupancy remains low after the stop codon. Moreover,
the Pol II subunit Rpb3, the serine 2 phosphorylation, and the elongation factors Spt5 and
Spn1 recover their occupancy levels at the pA site, suggesting a higher elongation rate for Pol
II and that these factors stay bound to the transcription machinery within the 3’ UTR. This
indicates that the previously reported early release of elongation factors for ribosomal genes [33]
is sharply positioned at the stop codon and also involves release of the cap-binding protein Cbp20,
the early termination factor Nrd1, and dephosphorylation of the CTD residues Ser5 and Ser7.
Taken together, cluster 38 suggests that highly expressed genes exhibit distinct transcription
mechanisms, characterized by efficient factor recruitments during early elongation and specific
processes of factor release around the stop codon.
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14.8 Not all termination regions are depleted of nucleosomes
Nucleosome depletion has been reported at the 3’-end of genes [188]. However, cluster 19, whose
634 genes terminate in state T1, does not show nucleosome depletion in this region. In contrast,
nucleosome depletion is a hallmark of all our promoter states. We therefore hypothesized that
the termination of genes in clusters other than cluster 19 overlaps with promoters of downstream
genes. Genes in clusters 1, 5, 6, 12, 32, 33, and 38 showed nucleosome-depleted termination
states P/T1 and P/T2. Their termination regions indeed overlap with a downstream promoter,
as indicated by TFIIB enrichment downstream of their pA site (Supplementary Figure 2 in
[113]). This supports previous reports that nucleosome depletion is not an intrinsic mark of
transcription termination [189]. Thus, bdHMM analysis of the genomic context of transcription
allows distinguishing canonical binding patterns from spurious ones caused by spill-over effects
from neighboring genes.
14.9 Promoter and termination states are enriched in known and new DNA
motifs
To detect putative functional DNA sequence elements associated with certain genomic states,
we performed de novo motif discovery on the nucleotide sequences underlying the bdHMM state
annotation using XXmotif [174]. In order to correct for local sequence properties like codon bias
we chose as negative sequence sets (not containing any motifs) the sequences with a length of
150 bp and a distance of 50 bp upstream of each state. The use of negative control sets strongly
improved the sensitivity during motif search (Methods section 10).
Promoter and termination states were enriched with sequence motifs (Figure 11). The state
P/T1, which is specific for cluster 38 genes, shows enrichment of TF-binding motifs with specific
functions such as ribosome biogenesis and general regulatory function as well as previously un-
known sequence motifs, in particular the highly abundant TTTTTTTTG motif present in 76%
of all P/T1 sequences (Figure 11). Termination state T1 contains motifs that are known to be
involved in the 3’-end formation and pA positioning [190] and one novel motif (TTTTTTTTA).
These motifs are located within the 3’ UTR of genes, in accordance with the state frequency peak
that we observe for state T1 (Figure 9B). The mixed state P/T2 also contains a motif associated
with 3’ end formation and previously unknown ones (Figure 11). For instance, it is enriched in
the motif TTTTTTTTC, which is similar to the one we found in P/T1 (Figure 11). Finally,
alternative states of the same phase of the transcription cycle were enriched for distinct motifs.
For instance, the Abf1 binding motif and the Mbp1-Swi6 binding motif were specifically found in
the promoter state P2 and not in the other promoter states. Together, this shows that bdHMM
analysis enhances the identification of novel functional DNA elements.
14.10 Comparison to standard HMM on chromatin states of human T-cells
We evaluated the performance of bdHMM on sequencing data and large genomes, by applying
bdHMM to a dataset of 41 chromatin marks in human T-cells [150]. The chromatin mark data had
been binarized into presence/absence of each mark at a resolution of 200bp bins and analyzed with
a standard HMM approach (ChromHMM) [151]. To handle the binarized chromatin marks data
defined by [150], we extended bdHMM and included binary (Bernoulli) emission distributions.
We fixed the emission distributions during bdHMM learning, allowing a direct comparison of
bdHMM states to HMM states. Moreover, this ensured that differences in the result are only due
to differences in the modeling of state transitions. We developed a directionality score (Methods
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Figure 11: Promoter and termination states are enriched in DNA motifs. De novo motif search in
the DNA sequences underlying the genomic state annotation discovered motifs in promoter states and
termination states. A short functional description, known binders and the frequency in the sequence set,
which was used in the analysis are shown. P2 is enriched in motifs of general transcriptional regulators
and chromatin remodelers. T1 contains motifs which are known to be involved in the 3’ end formation and
polyA positioning. P/T1 is enriched with ribosomal, cell-cycle specific and general transcription factors.
P/T2 contains motifs involved in transcription initiation and termination. P1 is enriched with a single
motif, that highly resembles OPI1.
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section 11) to decide that in the bdHMM, 35 out of a total of 51 ChromHMM states are modeled
as directed state pairs and 16 ChromHMM states are modeled as undirected states. Consistently,
we identified directed chromatin states around transcribed, but not at repressed or repetitive
regions (Supplementary Figure 5 in [113]). Up to state directionality, 83% of state annotations
agreed between the two methods (Methods section 11). Comparison of the ChromHMM with
the bdHMM transitions revealed that in ChromHMM, transition probabilities between two states
are similar in both directions (Figure 12C), whereas the bdHMM can resolve the true order of
chromatin states (Figure 12A,B, Supplementary Figure 6 in [113]). For example, transitions
from state 6 into states 2 and 3 are high for the forward direction, but low for the reverse
drection. In contrast, transitions from states 2 and 3 into state 6 are high in reverse, but low
in forward direction (Figure 12B). However, all of these transitions are high in the symmetric
ChromHMM model (Figure 12C), demonstrating that bdHMM adds previously unexploited and
valuable information to HMM-based analyses by uncoupling the underlying state directionality
of genomic processes. Analysis of promoter and transcribed state frequencies at the TSS showed
that state annotations matched the reading (sense) direction of the transcribed loci with up
to 85% (Supplementary Figure 7 in [113]). Promoter states showed pronounced peaks in sense
direction at the TSS, which are further downstream followed by high frequencies of (sense) 5’
proximal transcribed states. We conclude that bdHMM significantly improves the annotation of
the human epigenome, because it correctly recovers the flow of chromatin states as they occur
during transcription.
14.11 Discussion
We introduced bidirectional Hidden Markov Models (bdHMMs), a method for de novo and un-
biased inference of directed genomic states from genome-wide profiling data. In contrast to
previously described HMM-based approaches, bdHMM explicitly models directed genomic pro-
cesses. It allows for the integration of strand-specific experimental data such as RNA expression
profiles together with non-strand-specific data, such as ChIP occupancy data, and outperforms
standard HMM in genomic feature annotation. The open-source package STAN provides a fast,
multiprocessing implementation that can process the human chromatin data set in less than one
day.
Application of bdHMM analysis significantly improved insights into previously defined combina-
torial chromatin marks [150], indicating the presence of directed chromatin state patterns around
the transcribed, but not the repressed portion of the human genome. Our analysis of gene tran-
scription in the budding yeast enabled us to automatically recover the majority of known and
even new Pol II transcription units at a higher accuracy than standard HMM. We could assign
different directed genomic states that are characterized by the presence of different transcription
factors and Pol II CTD modification marks.
The most significant advance of bdHMM analysis over previous methods is its potential to de
novo identify characteristic sequences (patterns) of directed states on the genome. These patterns
identify gene-specific variation in transcription - or other directed processes - that were previ-
ously hidden by metagene analysis of experimental data. Metagene analysis derives only average
profiles for groups of genes defined beforehand, and is thus biased towards annotated genes. In
contrast, bdHMM allows investigating variations in the sequence of genomic states associated
with transcription. This is done by first identifying distinct genomic states de novo and then
clustering genes based on the succession of these genomic states. This analysis was consistent
with a general transcription cycle and uniform transitions of a core Pol II transcription complex
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Figure 12: Application of bdHMM to chromatin modifications in human T-cells identifies direction of
chromatin states. (A) Example of chromatin state annotation of ChromHMM and bdHMM (bottom
tracks) with RefSeq gene annotation and input signal. State direction matches gene orientation of an-
notated convergent genes and divergent genes. The log-transformed signal [150] of all 41 data tracks is
shown in black on top. Binarized input signal is shown for 18 acetylation marks in blue, 20 methylation
marks in red and CTCF/PolII/H2A.Z in brown. (B) bdHMM transitions between promoter-associated
states 1-11 are shown for forward and reverse states. While the asymetric, transposed structure of these
two submatrices (i.e. transition probabilities favor one direction for pairs aij andaji) uncouple the two
reading directions, the symmetric ChromHMM transition matrix (C) hides the underlying directed flow
of chromatin states.
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that occurs at all genes [33, 78, 184]. On the other hand, it also indicated gene-specific varia-
tions to the general transcription cycle, because the resulting clusters differed markedly in the
sequence of their genomic states. First, a few dozen genes that apparently show Nrd1-mediated
transcription attenuation are shown here to lack elongation factors Ctk1 and Paf1, suggesting
that transcription attenuation occurs before Ctk1 and Paf1 are recruited. Second, we provide ev-
idence for a distinct mechanism for highly expressed genes leading to the immediate recruitment
of a full complement of Pol II-associated factors downstream of the transcription start site. Third,
we found that nucleosome depletion is not a necessary feature of transcription termination.
Thus, we foresee bdHMMs to be instrumental for studying gene transcription and other directed
genomic processes, such as DNA replication, recombination or DNA repair.
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15 Accurate promoter and enhancer identification in 127 EN-
CODE and Roadmap Epigenomics cell types and tissues by
GenoSTAN
The results presented in this section are part of the manuscript “Acurate promoter and enhancer
identification in 127 ENCODE and Roadmap Epigenomics cell types and tissues by GenoSTAN”,
which was submitted for publication. For detailed author contributions see page ix.
Transcription is tightly regulated by cis-regulatory DNA elements known as promoters and en-
hancers. These elements control development, cell fate and may lead to disease if impaired.
A promoter is functionally defined as a region that regulates transcription of a gene, located
upstream and in close proximity to the transcription start sites (TSSs) [191]. In contrast, an
enhancer was originally functionally defined as a DNA element that can increase expression of
a gene over a long distance in an orientation-independent fashion relative to the gene [10]. The
functional definition of enhancers and promoters leads to practical difficulties for their genome-
wide identification because the direct measurement of the regulatory activity of genomic regions
is hard, with current approaches leading to contradicting results [192,193,194].
Since the direct measurement of cis-regulatory activity is challenging, a biochemical character-
ization of the chromatin at these elements based on histone modifications, DNA accessibility,
and transcription factor binding has been proposed [14, 101, 150, 195, 196]. This approach lever-
ages extensive genome-wide datasets of chromatin-immunoprecipitation followed by sequencing
(ChIP-Seq) of transcription factors (TFs), histone modifications, or Cap analysis gene expression
(CAGE) that have been generated by collaborative projects such as ENCODE [93, 197], NIH
Roadmap Epigenomics [110], BLUEPRINT [198] and FANTOM [199,200].
In this context, the computational approaches employed to classify genomic regions as enhancers
or promoters play a decisive role [195, 196]. As the experimental data are heterogeneous, we
generally refer to them as tracks. Several studies used supervised learning techniques to predict
enhancers based on tracks such as histone modifications or P300 binding (e.g. [201,202,203,204]).
However, a training set of validated enhancers is needed in this case, which is hard to define since
only few enhancers have been validated experimentally so far and these might be biased towards
specific enhancer subclasses. Alternatively, unsupervised learning algorithms were developed to
identify promoters and enhancers from combinations of histone marks and protein-DNA inter-
actions alone [93, 101, 102, 103, 110, 150, 155, 205]. These unsupervised methods perform genome
segmentation, i.e. they model the genome as a succession of segments in different chromatin
states defined by characteristic combinations of histone marks and protein-DNA interactions
found recurrently throughout the genome. All popular genome segmentations are based on hid-
den Markov models [112]. However, these methods differ in the way the distribution of ChIP-seq
signals for each chromatin state is modeled. ChromHMM [103,150,151], one of the two methods
applied by the ENCODE consortium, requires binarized ChIP-seq signals that are then modeled
with independent Bernoulli distributions. Consequently, the performance of ChromHMM highly
depends on the non-trivial choice of a proper binarization cutoff. Moreover, quantitative informa-
tion is lost with this approach, which is especially important for distinguishing promoters from
enhancers since these elements are both marked with H3K4me1 and H3K4me3, but at different
ratios [62]. Segway [101, 102], the other method applied by the ENCODE consortium, uses in-
dependent Gaussian distributions of log-transformed and smoothed ChIP-seq signal. Although
Segway preserves some quantitative information, the transformation of the original count data
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leads to variance estimation difficulties for very low counts. Therefore, Segway further makes
the strong assumption that all tracks have the same variance. Recently, EpicSeg [154] used a
negative multinomial distribution to directly model the read counts without the need for data
transformations. However, similar to the variance model of Segway, the EpicSeg model leads to
a common dispersion (the parameter adjusting the variance of the negative multinomial) for all
tracks. Moreover, EpicSeg does not provide a way to correct for sequencing depth, which makes
the application to data sets with multiple cell types with varying library sizes difficult. Also,
EpicSeg has been applied only to three cell types so far [154]. These methods not only differ in
their modeling assumptions but also lead to very different results. In the K562 cell line for in-
stance, ChromHMM identified 22,323 enhancers [93], Segway 38,922 enhancers [93], and EpicSeg
53,982 enhancers [154]. Altogether, improved methods and detailed benchmarkings are required
for a reliable annotation of transcriptional cis-regulatory elements.
Here we propose a new unsupervised genome segmentation algorithm, GenoSTAN (Genomic
State Annotation from sequencing experiments), which overcomes limitations of current state-
of-the-art models. GenoSTAN learns chromatin states directly from sequencing data without
the need of data transformation, while still having track-specific variance models. We applied
GenoSTAN to a total of 127 cell types and tissues covering 16 datasets of ENCODE and all 111
datasets of the Roadmap Epigenomics project as well as another ENCODE ChIP-seq dataset for
the K562 cell line. GenoSTAN consistently performed better when benchmarked against Segway,
ChromHMM and EpicSeg segmentations using independent evidence for activity of promoter and
enhancer regions. Co-binding analysis of TFs reveals that promoters and enhancers both shared
the Polymerase II core transcription machinery and general TFs, but they are bound by distinct
TF regulatory modules and differ in many biophysical properties. Moreover, GenoSTAN enhancer
and promoter annotations had a higher enrichment for complex trait-associated genetic variants
than previous annotations, demonstrating the advantage of GenoSTAN and our chromatin state
map to understand genotype-phenotype relationships and genetic disease.
15.1 Modeling of sequencing data with Poisson-lognormal and negative bino-
mial distributions
We developed a new genomic segmentation algorithm, GenoSTAN, which implements hidden
Markov models with more flexible multivariate count distributions than previously proposed.
GenoSTAN supports two multivariate discrete emission functions, the Poisson-lognormal dis-
tribution and the negative binomial distribution. For the sake of reducing running time, the
components of these multivariate distributions are assumed to be independent. However, the
variance is modeled separately for each state and each track, which provides a more realistic vari-
ance model than current approaches. To be applicable to data sets with replicate experiments
or multiple cell types, GenoSTAN corrects for different library sizes of experiments (Methods
section 8). All parameters are learnt directly from the data, leaving the number of chromatin
states as the only parameter to be manually set. We provide an efficient implementation of the
Baum-Welch algorithm for inference of model parameters, which can be run in a parallelized
fashion using multiple cores. The method is implemented as part of our prevsiouy published
R/Bioconductor package STAN [113], which is freely available from http://bioconductor.org/.
Altogether, GenoSTAN uniquely combines flexible count distributions, short running times, and
minimal number of manually entered parameters (Figure 13A).
We performed an extensive benchmarking of GenoSTAN against alternative methods (Figure
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Figure 13: Overview of chromatin state annotation methods and study design. (A) Comparison of
features of GenoSTAN against three previous chromatin state annotation algorithms. (B) Description of
the three benchmark sets used in this study. GenoSTAN is benchmarked against published chromatin
state annotations using ChromHMM (’ChromHMM-ENCODE’ [93, 102], ’ChromHMM-Nature’ [103],
’ChromHMM-15’, ’-18’ and ’-25’ [110]), Segway (’Segway-ENCODE’ [93, 102], ’Segway-nmeth’ [101] and
’Segway-Reg.Build’ [155]) and EpicSeg [154].
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13B). Benchmark I compares GenoSTAN and the three alternative methods for the K562 cell line.
K562 is a major model system to study human transcription and the ENCODE cell line with the
largest number of experiments [93]. Moreover, all three other methods (ChromHMM, Segway, and
EpicSeg) had been run by their own authors for K562, so that the algorithm parameters for these
annotations can be assumed to have been set at best expert knowledge. Benchmark II compares
methods for all 127 cell types and tissues provided by ENCODE and Roadmap Epigenomics.
This is the largest benchmark dataset of all three we considered but also the one with the least
number of common tracks (5 chromatin marks: H3K4me1, H3K4me3, H3K36me3, H3K27me3,
and H3K9me3, Figure 13B). Benchmark III compares results for a subset of 20 ENCODE and
Roadmap Epigenomics cell types and tissues which had moreover H3K27ac, H3K9ac ChIP-seq and
DNAse I hypersensitivity data (DNAse-Seq). This distinction allowed to provide more accurate
annotations for the better characterized cell types and tissues. For benchmark II and benchmark
III only annotations for the method ChomHMM were available to compare against GenoSTAN
annotation. Figure 13B lists all model names and studies that were considered.
15.2 Benchmark I: Improved chromatin state annotation in human K562 cells
We first fitted two GenoSTAN models, one with Poisson-lognormal emissions (henceforth referred
to as GenoSTAN-Poilog-K562 model) and one with negative binomial emissions (GenoSTAN-nb-
K562 model) to a dataset of ChIP-seq data of 9 histone modifications, of the histone acetyl-
transferase P300, and DNA accessibility (by DNase-Seq) data for the K562 cell line at 200 bp
binning resolution (Methods section 12). As pointed out by others [101, 150], there is no purely
statistical criterion for choosing the number of states from the data of practical usage in such a
setting. In practice, the number of states is manually defined by trading off goodness of fit against
interpretability of the model [101, 113, 150]. For GenoSTAN-Poilog-K562, we used 18 chromatin
states. For GenoSTAN-nb-K562, we used 23 states, since lower state numbers did not provide
enough resolution to give a fine-grained map of chromatin states on this data set (Methods sec-
tion 12). Figure 14A compares the two GenoSTAN segmentations to segmentations from other
studies using ChromHMM, Segway and EpicSeg on a region containing the TAL1 gene together
with three known enhancers [16,93,102,154].
15.2.1 Chromatin states recover biologically meaningful features
In order to assign biologically meaningful labels to each state of the Poilog-K562 and of the
nb-K562 GenoSTAN models, we investigated their read coverage distributions and overlapped
the occurrence of a state in the genome with known genomic features. In line with previous
studies, this led to the definition of promoter, enhancer, repressed, actively transcribed and
low coverage states [102, 103, 154]. The median read coverage in state segments and genomic
distributions were very similar for both the Poilog-K562 and the nb-K562 models (Figure 14B,
Appendix Figure A1). Promoter states were characterized by a low (< 1) H3K4me1/H3K4me3
ratio, in contrast to enhancer states which showed a high ratio (> 1). Further, P300 levels were
roughly two-fold higher in the enhancer state, which is in accordance with previous observations
[62, 206, 207]. Promoter (Prom) states were located close to annotated GENCODE TSSs [104],
with a median distance of 220 bp for GenoSTAN-Poilog-K562 and 400 bp for GenoSTAN-nb-
K562 model. Enhancer states (Enh) on the other hand were located further away from TSSs,
with a median distance of 3.6 kb (Poilog-K562) (respectively 5.8 kb for nb-K562, Figure 14B,
Appendix Figure A1). Promoter and enhancer states also differed in their DNA sequence features.
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Figure 14: Chromatin states fitted on Benchmark I using GenoSTAN. (A) GenoSTAN segmentations
are shown with published segmentations using ChromHMM-ENCODE [93], Segway-ENCODE [93] and
EpicSeg [154] at the TAL1 gene and three known enhancers. GenoSTAN-Poilog-K562 correctly recalls all
known promoter and enhancer regions. GenoSTAN-nb-K562 misses the upstream enhancer. ChromHMM-
ENCODE misclassifies most of the downstream enhancer region as promoter. (B) Median read coverage
of GenoSTAN-Poilog-K562 chromatin states (left), their number of annotated segments in the genome,
their median width and distance to the closest GENCODE TSS (middle). The right panel shows recall
of genomic regions by chromatin states.
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45% of CpG islands were located within promoter states (strong, weak and promoter flanking
states) in both models, but only 3% in enhancer states (strong, weak, enhancer flanking states,
Figure 14B, Appendix Figure A1). While promoter states mostly recovered stable TSSs, enhancer
states were located at unstable TSSs (GRO-cap TSSs that are not recovered by the GENCODE
annotation), which supports previous findings [13]. Furthermore, both models (GenoSTAN-nb-
K562 and GenoSTAN-Poilog-K562) contained 3 states, that we classified as “actively transcribed
states”, which were characterized by high values of H3K36me3 and overlap with UTRs, introns
and exons. Two out of three “transcribed” states were also enriched in promoter associated
marks (H3K4me1-3, H3K27ac, H3K9ac) and H4K20me1 and thus represented 5’ transitions in
transcription. Moreover, both models fitted four repressed states showing high read coverage of
H3K27me3. Two of these states also exhibited high DNase-Seq and promoter/enhancer associated
histone modification signals, suggesting that these states might reflect repressed regulatory regions
(ReprEnh, ReprD). These elements were distal to annotated GENCODE TSSs (median distance:
5.2-11.8 kb). ReprEnh states were also enriched in P300 and recovered 0.2% of CpG islands,
while ReprD states had lower P300 levels and recovered 8-9% of CpG islands in the genome
(Figure 14B, Appendix Figure A1). The remaining states exhibited low coverage in chromatin
marks and therefore were labeled as “low” states. Altogether, GenoSTAN accurately recovered
many features of known chromatin states and provided a high resolution map of these in K562.
15.2.2 High variation of enhancer predictions between chromatin state annotations
of different studies
To assess the consistency of promoter and enhancer predictions across studies, we compared the
GenoSTAN segmentations to other published segmentations in K562 by ChromHMM (’ChromHMM-
ENCODE’ [93,102] and ’ChromHMM-Nature’ [103]), Segway (’Segway-ENCODE’ [93,102], ’Segway-
nmeth’ [101] and ’Segway-Reg.Build’ [155]) and EpicSeg [154]. We computed pairwise Jaccard
indices (the ratio of the number of common elements over all elements predicted by two methods)
of promoter and enhancer states to quantify the agreeement between the predictions of the dif-
ferent studies (Appendix Figure A2). Promoter state annotations generally agreed well (median
Jaccard-Index: 0.78). However, enhancer prediction varied more (median Jaccard Index: 0.48),
suggesting that enhancers are more difficult to annotate. This variation of enhancer calls was
also reflected in the different numbers of annotated enhancer segments, which had been shown
to vary greatly between different prediction methods [201]. The number of enhancer segments
ranged from 10,932 segments in GenoSTAN-Poilog-K562 to 80,043 segments in one Segway an-
notation [101] (Appendix Table A1). Therefore, a thorough assessment of these predictions was
necessary to provide a robust and accurate prediction of these elements.
15.2.3 Comparison of GenoSTAN with published chromatin state annotations
In order to benchmark the different segmentations, we used independent data including evi-
dence of transcriptional activity (GRO-cap TSSs [13]), of transcription factor binding (ENCODE
high occupancy target, or HOT regions [197], and ENCODE TF binding sites [93]), and of cis-
regulatory activity (enhancer activity assessed by reporter assays [193]), which are all expected
to be characteristics of promoters and enhancers. Transcription initiation activity is not only
the hallmark of promoters, but also of enhancers [3, 13, 199, 200]. To benchmark the predictions
using evidence for transcription, we used published data from a protocol called GRO-cap [13], a
nuclear run-on protocol, which very sensitively maps transcription start sites genome-wide. To
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this end, we sorted for each method chromatin states by their overlap with GRO-cap TSSs by
decreasing precision. Starting with the most precise state (i.e. highest overlap with TSSs) we
calculated cumulative recall and false discovery rate (FDR) by subsequently adding states with
decreasing precision (Figure 15A). GenoSTAN-Poilog-K562 had the highest recall and the lowest
FDR (Methods section 12, Figure 15A). GenoSTAN-nb-K562 performed similar to other segmen-
tations (Segway-Reg. Build, ChromHMM-ENCODE). In particular, 94% of GenoSTAN-Poilog-
K562 promoters (Prom.11) and 81% of its enhancer regions (Enh.15) overlapped with GRO-cap
TSSs. This compares to 85% (Prom.16) and 65% (Enh.6) of GenoSTAN-nb-K562 and 89% (Tss)
and 52% (Enh) of ChromHMM-ENCODE promoter and enhancer regions. Interestingly, the two
ChromHMM segmentations (ChromHMM-ENCODE [93, 102], ChromHMM-Nature [103]) had
very different accuracies for TSSs, which might be due to different data sets or cutoffs used for
ChIP-seq binarization in the two studies. In contrast, the overall accuracy of the Segway anno-
tations was comparable across studies. This comparison shows that GenoSTAN chromatin state
annotation identifies putative promoters and enhancers which show transcriptional activity more
frequently than previous annotations.
GRO-cap is a very sensitive method that captures also a large amount of TSSs of unstable tran-
scripts [13]. However it is limited to capped RNA species, misses RNAs below the detection
threshold and cannot be used to validate repressed (i.e. transcriptionally inactive) regulatory
elements. To address these shortcomings we used two additional independent features, TF bind-
ing and HOT regions. The binding of TFs to a region of DNA is a pre-requisite for potential
regulatory function and transcriptional activity. High Occupancy of Target (HOT) regions are
genomic regions which are bound by a large number of different transcription-related factors [197],
which were shown to function as enhancers [208] and are enriched in disease- and trait-associated
genetic variants [209]. As for the benchmark with TSSs, we sorted chromatin states by overlap
with HOT regions by decreasing precision and calculated cumulative recall and FDR (Figure
15B). The best performing segmentations for HOT regions were GenoSTAN-Poilog-K562 and
GenoSTAN-nb-K562, followed by ChromHMM-ENCODE. The ordering of states with HOT re-
gions was indeed different from the GRO-cap TSSs benchmark. Additionally to GenoSTAN
promoter and enhancer states, the repressed enhancer state frequently overlapped with HOT re-
gions with an overall precision of 81% (GenoSTAN-Poilog-K562) and 77% (GenoSTAN-nb-K562).
In comparison, the top three ChromHMM-ENCODE states had together a precision of 67%. All
other segmentation methods showed a lower precision and recall for HOT regions. This was also
reflected in the frequency of individual TF binding sites at enhancer regions, which were generally
higher in GenoSTAN enhancer states than in other segmentations (Figure 15C). In particular,
only a very small fraction of EpicSeg and Segway-nmeth enhancers were found to be bound by
TFs. EpicSeg and Segway-nmeth segmentations were also those with the highest number of pre-
dicted enhancers, suggesting that many of these predictions are spurious.
Next, we calculated the recall of FANTOM5 promoters [200] and enhancers [199] to assess how
well the models distinguish promoters from enhancers, as it was evident from inspection of spe-
cific examples that this distinction was difficult to be established by current methods (Figure
15D). The FANTOM5 consortium have performed extensive mapping of capped transcripts 5’
ends using CAGE and defined enhancers and promoters based on transcriptional activity pattern.
FANTOM5 enhancers were defined as regions showing balanced bidirectional capped transcripts,
a hallmark of enhancer RNAs [199], whereas FANTOM5 promoters were defined as regions where
transcription was biased towards one direction. The FANTOM5 annotation of enhancers and
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Figure 15: Comparison of GenoSTAN to other published segmentations on benchmark set I. (A) Perfor-
mance of chromatin states in recovering GRO-cap transcription start sites. Cumulative FDR and recall
are calculated by subsequently adding states (in order of increasing FDR). (B) The same as in (A) for
ENCODE HOT regions. (C) The fraction of predicted enhancer segments bound by individual TFs is
shown for different studies. GenoSTAN enhancers are more frequently bound by TFs than those from
other studies. (D) Recall of FANTOM5 promoters and enhancers which are active in K562 (i.e. over-
lapping with a GRO-cap TSS and an ENCODE DNase hypersnesitivity site) by predicted promoters
and enhancers is plotted to assess how well models distinguish promoters from enhancers. (E) Predicted
enhancers show significantly higher activity than repressed and low coverage regions as measured by a
reporter assay (’*’, ’**’ and ’***’ indicate p-values <0.05, 0,01 and 0.001). (F) Comparison of experimetal
measures of enhancer activity between different studies.
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promoters could not entirely replace a chromatin state based approach because (i) the use of
expression data in FANTOM5 limits the identified regulatory regions to transcriptionally active
elements and (ii) CAGE was shown to be not as sensitive to rapidly degraded transcripts as GRO-
cap and therefore might miss regulatory enhancers with unstable transcripts [13]. Nonetheless,
FANTOM5 provides an annotation of enhancers and promoters based on independent data that
is well suited to assess how well the models distinguish promoters from enhancers. We filtered
the FANTOM5 annotation to promoters and enhancers for activity in K562 by overlapping them
with DHS [93] and GRO-cap TSSs [13]. We considered that a promoter state performed well,
when the recall of FANTOM5 promoters was high and the recall of FANTOM5 enhancers was
low and vice versa for enhancer states. GenoSTAN-Poilog-K562 and ChromHMM-nature en-
hancer states recall most FANTOM5 enhancers (60%, Figure 15D, Appendix Table A2). For
enhancer states, the recall of FANTOM5 promoters was around 10% except for those of Segway-
ENCODE, which recalls almost 35% of FANTOM5 promoters and EpicSeg which recalls 21% of
FANTOM5 promoters. In accordance with this, many promoter regions were erroneously clas-
sified as enhancer regions in this segmentation (e.g. TAL1 promoter in Figure 14A). The recall
of FANTOM5 enhancers by promoter states was generally higher (17% - 37%). GenoSTAN-
Poilog-K562 and -nb-K562 recalled more than 90% of FANTOM5 promoters and around 20% of
FANTOM5 enhancers which is comparable to other studies (Segway-nmeth, ChromHMM-nature,
EpicSeg). ChromHMM-ENCODE promoter states had a comparable recall of FANTOM5 pro-
moters (92%), but higher recall of FANTOM5 enhancers (37%) (Figure 15D). This strong overlap
of ChromHMM-ENCODE promoters with FANTOM5-labeled enhancers is in accordance with our
observation that some enhancer regions were errenuously classified as promoters in ChromHMM-
ENCODE (Figure 14A). These results show that GenoSTAN segmentations distinguish promoters
from enhancers at similar or better accuracy than other segmentations.
So far we only used indirect evidence (TSSs, HOT regions, TF binding, FANTOM5 enhancer)
to draw conclusions about the cis-regulatory activity of a candidate enhancer. As additional and
direct evidence for the cis-regulatory activity of enhancer regions inferred by GenoSTAN, we over-
lapped our enhancers to genomic sequences that were previously tested for cis-regulatory activity
in a reporter assay, where candidate elements had been cloned into a plasmid upstream of the
promoter of a reporter gene [193]. Enhancers from GenoSTAN segmentations showed significantly
higher activity than repressed or low coverage regions (GenoSTAN-Poilog-K562 & GenoSTAN-
nb-K562: p-value < 0.001 wilcoxon-test, Figure 15E). Interestingly, repressed regions (marked by
H3K27me3) showed lower activity than low coverage regions. Moreover, GenoSTAN-Poilog-K562
enhancers showed significantly higher enhancer activity than those of three other studies (Figure
15F), including the original study (p-value < 0.01, ChromHMM-nature enhancers) by Kherad-
pour et al. [193]. This analyis shows that GenoSTAN has higher succes rate in predicting in vivo
enhancer activity than previous methods.
15.2.4 Comparison of the GenoSTAN, ChromHMM, Segway and EpicSeg algo-
rithms on a common dataset
The K562 genome segmentations of ChromHMM, Segway and EpicSeg used so far were de-
rived from different combinations of data tracks. To verify that the favorable performance of
GenoSTAN is mainly due to an improved modeling and not due to different data, we also ran
ChromHMM, Segway and EpicSeg on the same data as GenoSTAN-Poilog-K562 and GenoSTAN-
nb-K562 (Methods section 12). Both GenoSTAN-Poilog-K562 and GenoSTAN-nb-K562 had a
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lower FDR at a similar or higher recall than all three other methods (Appendix Figure A3).
Moreover, we found that changing the binarization for ChromHMM dramatically affected its
outcome. Without further manual processing of the data, ChromHMM fitted only one transcrip-
tionally active state, which modeled both promoters and enhancers, regardless of state number
(Appendix Figure A3). We suspected that the high read coverage in the H3K4me1 and H3K4me3
signal tracks made promoters and enhancers indistinguishable after binarization (H3K4me1 and
H3K4me3 were called present at both, promoters and enhancers, and they were both called ab-
sent elsewhere). When all data tracks were subsampled to the same (and lower) library size,
this problem was solved and ChromHMM fitted multiple transcriptionally active states thereby
distinguishing promoters from enhancers and, at the same time, increased in accuracy (Appendix
Figure A3). The same problem occurred for Segway, but changing Segway’s parameters did not
help distinguish different transcriptionally active chromatin states.
To make sure that these results did not depend on the arbitrary choice of the number of states, we
ran each method using 10 to 30 states (Methods section 12) and calculated the precision of each
state S for recalling HOT (respectively TSS) regions as the fraction of all segments annotated
with S that overlapped with a HOT (respectively TSS) region. For each number of states and
each segmentation algorithm, we determined the state with highest precision (Appendix Figure
A4A, B). Independently of the number of states, GenoSTAN-Poilog and GenoSTAN-nb consis-
tently performed best. Even at low state numbers, precision remained constantly high, while it
decreased considerably for other methods. We also derived an area under curve (AUC) score
for each model, to assess the spatial accuracy in calling TSSs or HOT regions (Appendix Figure
A4C, D and Methods section 12). Again, AUC scores were consistently highest for the GenoS-
TAN segmentations.
Altogether this extensive benchmark in the K562 cell line demonstrates that GenoSTAN-Poilog
and to a slightly lesser extent GenoSTAN-nb, outperforms current chromatin state annotation
algorithms for identifying enhancers and promoters.
15.3 Benchmark II and III: Chromatin state annotation for ENCODE and
Roadmap Epigenomics cell types and tissues
We next applied GenoSTAN to 127 cell types and tissues from ENCODE and Roadmap Epige-
nomics, the largest compendium of chromatin-related data, using genomic input and the five
chromatin marks H3K4me1, H3K4me3, H3K36me3, H3K27me3, and H3K9me3 that have been
profiled across the whole compendium [110] (Appendix Figure A5, Benchmark II, Figure 13B
for data tracks and model names). Moreover, we performed a dedicated analysis to 20 of these
cell types and tissues which had three further important data tracks: H3K27ac, H3K9ac and
DNase-Seq (Appendix Figure A6, Benchmark III, Figure 13B for data tracks and model names).
These further three tracks are important features of active promoters and enhancers, which can
lead to more precisely mapped enhancer boundaries [93]. We performed similar comparisons as
decribed above to the three available segmentations from the Roadmap Epigenomics project with
15, 18 and 25 states (ChromHMM-15, -18, and -25) [110,152]. All methods were less performant
than in Benchmark I, possibly due to lower read coverage or to less rich data. Nonetheless, the
GenoSTAN annotations consistently outperformed the existing ones. Specifically, this held when
assessing the recovery of FANTOM5 CAGE tags (Figure 16A, assessed for all 127 cell types
and tissues), of GRO-cap TSSs (Figure 16B assessed for the cell types with available GRO-Cap
TSSs), and of HOT regions (Figure 16C, assessed for the cell types with available HOT regions).
Moreover, both GenoSTAN models distinguished better promoters from enhancers than pre-
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vious annotations (Figure 16D, Appendix Table A2). The low accuracy of ChromHMM-15 and
ChromHMM-18 promoters might be caused by frequent state switching between the promoter and
promoter flanking state (Appendix Figure A7). Consequently, the number of promoter regions in
K562 was up to 30% higher in the ChromHMM-15 and -18 segmentations than in the GenoSTAN
or ChromHMM-25 segmentations (Appendix Table A1). The number of predicted enhancers (in
K562) also differed greatly. The ChromHMM-15 and -18 state models predict 92,824 (7_Enh)
and 22,678 (9_EnhA1) enhancers, while ChromHMM-25 predicts 12,706 and GenoSTAN-Poilog-
20 and -127 predict 15,655 and 45,955 enhancers (Appendix Table A1). Although GenoSTAN
predicted more enhancers than the ChromHMM-25 model, the fraction of putative enhancers
bound by individual TFs was greater (Figure 16E). For instance 46% (25%) of enhancers were
bound by Pol II in the GenoSTAN-Poilog-20 (-127) model, compared to 8%, 18% and 36% in the
ChromHMM 15, 18 and 25 state models. Also, the lineage-specific enhancer-binding transcription
factor TAL1 binds at 37% (GenoSTAN-Poilog-20) and 27% (GenoSTAN-Poilog-127) of predicted
enhancers. Conversely, 13%, 16% and 27% of putative enhancers were bound by TAL1 in the
respective 15, 18 and 25 state ChromHMM models (Figure 16E). Collectively, these results show
that the improved performance of GenoSTAN is not restricted to the K562 dataset.
15.4 Cell-type specific enrichment of disease- and other complex trait-associated
genetic variants at promoters and enhancers
Previous studies showed that disease-associated genetic variants are enriched in potential reg-
ulatory regions [103, 110, 210, 211, 212, 213] demonstrating the need for accurate maps of these
elements to understand genotype-phenotype relationships and genetic disease. To study the po-
tential impact of variants in regulatory regions on various traits and diseases, we overlapped
our enhancer and promoter annotations from 127 cell types and tissues (Benchmark II, Fig-
ure 13B) with phenotype-associated genetic variants from the NHGRI genome-wide assocation
studies catalog (NHGRI GWAS Catalog [181]). First, we intersected trait-associated variants
with enhancer and promoter states (GenoSTAN-Poilog-127). Overall, 37% of all trait-associated
SNPs were located in potential enhancers and 7% in potential promoters. The number of traits
significantly enriched (at FDR <0.05) with enhancers or promoters in at least one cell type or tis-
sue was larger for GenoSTAN-Poilog-127 (69 traits for GenoSTAN-Poilog-127 for enhancers and
20 traits for promoters, Methods section 12) than for the best performing ChromHMM-model
(ChromHMM-15, 64 traits for enhancers and 18 traits for promoters). The better performance
of GenoSTAN-Poilog-127 was found at all FDR cutoffs (Appendix Figure A8). To control for
the fact that methods can differ among each other regarding the length of the promoters and en-
hancers they predict, we furthermore computed the recalls of GWAS variants for a fixed genomic
coverage. Restricting to a total genomic coverage of 2% (random subsetting, also allowing confi-
dence interval computation, Methods section 12), enhancers of all GenoSTAN models overlapped
a higher fraction of GWAS variants at a similar to better per base pair density compared to the
current ChromHMM annotations (Figure 17A). The same trend was observed for promoters when
restricting to 1% of genomic coverage (Figure 17B). The improved overlap with trait-associated
variants indicates that GenoSTAN annotation has a higher enrichment for functional elements
than the current annotation.
In accordance with previous studies [103, 110] we found that individual variants were strongly
enriched in enhancer or promoter states specifically active in the relevant cell types or tissues
(Figure 17C, Appendix Figure A8C). Variants associated with height were significantly associated
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Figure 17: Enrichments of genetic variants associated with diverse traits in enhancers are specific to the
relevant cell types or tissues. (A) Median SNP recall and frequency was calculated for enhancer states
in different segmentations by restricting it to a total genomic coverage of 2% (100 samples of random
subsetting) to control for different number of enhancer calls between the segmentations. Error bars show
the 95% confidence interval. (B) The same as in (A) but for promoters. (C) The heatmap shows the
-log10(p-value) of significantly enriched traits in enhancer states (GenoSTAN-Poilog-127, p-value < 0.001,
marked by ’*’). Only cell types and tissues where at least one trait was significantly enriched are shown.
P-values were adjusted for multiple testing using the Benjamin-Hochberg correction.
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with osteoblasts (at FDR <0.001 here and after, performed on Benchmark II for consistency
across cell types and tissues). Variants associated with immune response or autoimmune disorders
were enriched in B- and T-cell enhancers (Figure 17C) and promoters (Appendix Figure A8C).
These incude for instance HIV-1 control, autoimmune disease associated SNPs for systemic lupus
erythematosus, inflammatory bowel disease, Ulcerative colitis, Rheumatoid arthritis, Primary
biliary cirrhosis and Multiple sclerosis. Variants associated with electrocardiographic traits and
QT interval were enriched in fetal heart enhancers. SNPs associated with colorectal cancer
were enriched in enhancers specific to the digestive system. These results illustrate that the
annotation of potential promoters and enhancers generated in this study can be of great use
for interpreting genetic variants associated, and underscore the importance of cell-type or tissue
specific annotations.
15.5 A novel annotation of enhancers and promoters in human cell types and
tissues
We then compiled the results from the best performing annotations for each cell type and tissue
into a single annotation file. The combined annotation file and all individual chromatin state
annotations are available at http://i12g-gagneurweb.in.tum.de/public/paper/GenoSTAN. For the
combined annotation file, we chose GenoSTAN with Poisson-lognormal in every instance, as it
performed best in almost every comparison we conducted. We used the results from benchmark I
for K562, from benchmark III for the 20 cell types and tissues, and from benchmark II for all the
remaining Roadmap Epigenomics cell types and tissues. Overall, our annotation reports typically
between 8,945 and 16,750 (10% and 90% quantiles of number of promoters across all 127 cell types
and tissues) active promoters per cell type or tissue. This number is consistent with the typical
number of expressed genes per tissue (in 11,953 to 16,869 range, [214]). However, the median
width of these elements depends on the data on which the annation was based. For the benchmark
III dataset, promoters are much narrower (800bp median) than for the K562 annotations (1.4
kb, Benchmark I data sst), suggesting that promoter regions in the 20 cell types more accurately
recover DNase hypersensitivity sites (DHS) of the core promoter (Figure 14, Appendix Figure
A6). The number of enhancers per cell type or tissue varied more greatly (between 8,208 and
33,596 for the 10% and 90% quantiles). The large variation of the number of enhancers might
be partly due to differences of sensitivity in complex biological samples. Consistent with this
hypothesis, much fewer enhancers were identified in tissues than in primary cells and cell lines
(Appendix Figure A9) likely because enhancers that are active only in a small subsets of all cell
types present of a tissue may be not detected. As more cell-type specific data will be available,
improved maps can be generated. The GenoSTAN software, which is publicly available, will be
instrumental to update these genomic annotations.
15.6 Promoters and enhancers have a distinct TF regulatory landscape
The biochemical distinction between enhancers and promoters is a topic of debate [14, 195]. We
explored to which extent enhancers and promoters are differentially bound by TFs using the
K562 cell line dataset because i) we obtained the most accurate annotation for this cell line
(GenoSTAN-Poilog-K562, Benchmark I) and ii) ChIP-seq data was available for as many as 101
TFs in this cell line [93]. Nine TF modules were defined by clustering based on binding pat-
tern similarity across enhancers and promoters (Methods section 12, Figure 18). These 9 TF
modules were further characterized by the propensity of their TFs to bind promoters, enhancers
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Figure 18: Promoters and enhancers have a distinctive TF regulatory landscape. Co-binding (left) and
enrichment of transcription factor binding sites (right) in chromatin states (GenoSTAN-Poilog-K562) for
101 transcription factors in K562 reveals TF regulatory modules with distinct binding preferences for
promoters, enhancers and repressed regions. The co-binding is depicted as the frequency of binding sites
of two TFs that co-occur in a chromatin state divided by the number of all binding sites of the two TFs
(Jaccard index). For each TF, enrichments were normalized to sum up to 1 across all 18 chromatin states
of GenoSTAN-Poilog-K562.
or both (Figure 18). In accordance with previous studies [180, 215], this recovered many com-
plexes and promoter-associated and enhancer-associated proteins, including the CTCF/cohesin
complex (CTCF, Rad21, SMC3, Znf143), the AP-1 complex (Jun, JunB, FOSL1, FOS), Pol3,
promoter and enhancer associated modules, and factors associated with chromatin repression
(EZH2, HDAC6).
Moreover, the modules identified provided insights into the distinction of promoters and en-
hancers. On the one hand, some TFs are common to both enhancers and promoters, which
supports previous reports [14, 199]. In accordance with the recent finding of widespread tran-
scription at enhancers [13], Pol II and multifunctional TFs Myc, Max, and MAZ [216] are part of a
TF module - which we called the Promoter-Enhancer-Module (PEM) - which had approximately
equal binding preferences for promoter and enhancer states, but also co-localized with other TFs
specifically binding enhancers or promoters (Figure 18).
On the other hand enhancers and promoters were also bound by distinct TFs, which is con-
sistent with previously reported TF co-occurrence patterns at gene-proximal and gene-distal
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sites [180, 215]. Among the promoter and enhancer-associated proteins we defined Promoter
module 1 and 2 (PM1, PM2), Enhancer module 1 and 2 (EM1, EM2), which had a strong prefer-
ence for binding either a promoter or an enhancer, but exhibited different co-binding rates (Figure
18). Promoter module 1 contained TFs which were specifically enriched in promoter states and
associated with basic promoter functions, such as chromatin remodeling (CHD1, CHD2), tran-
scription initiation or elongation (TBP, TAF1, CCNT2, SP1) and other TFs involved in the
regulation of specific gene classes (e.g. cell cycle: E2F4) [216]. However, it also included TFs
known as transcriptional repressors (e.g. Mxi1, a potential tumor suppressor, which negatively
regulates Myc). While TFs in PM1 showed a high co-binding rate, PM2 factors exhibited low
co-binding. This might be partially explained by lower efficiency of the ChIP, since PM2 also
contained general TFs such as TFIIB, TFIIF or the Serine 2 phospho-isoform of Pol II, which are
expected to co-localize with other general TFs from PM1.
EM1 contained TFs with high co-binding rate, which included TAL1, an important lineage-specific
regulator for erythroid development (K562 are erythroleukemia cells) and which had been shown
to interact with CEBPB, GATA1 and GATA2 at gene-distal loci [215,217]. It also contained the
enhancer-specific transcription factor P300 [207] and transcriptional activators (e.g. ATF1) and
repressors (e.g. HDAC2, REST) [216]. Analogously to PM2, EM2 contained enhancer-specific
transcriptional activators and repressors with a low co-binding rate.
Altogether this analysis highlights the common and distinctive TF binding properties of enhancers
and promoters.
15.7 Discussion
We introduced GenoSTAN, a method for de novo and unbiased inference of chromatin states
from genome-wide profiling data. In contrast to previously described methods for chromatin
state annotation, GenoSTAN directly models read counts, thus avoiding data transformation and
the manual tuning of thresholds (as in ChromHMM and Segway), and variance is not shared
between data tracks or states (as in EpicSeg and Segway) [101, 150, 154]. GenoSTAN is released
as part of the open-source R/Bioconductor package STAN [113, 156, 161], which provides a fast,
multiprocessing implementation that can process data from 127 human cell types in 3-6 days
(GenoSTAN-Poilog-127: 6 days, -nb: 3 days).
Application of GenoSTAN significantly improved chromatin state maps of 127 cell types and
tissues from the ENCODE and Roadmap Epigenomics projects [93, 110]. Binding of enhancer-
associated co-activator CBP and histone acetyltransferase P300 was used by several studies for
the genome-wide prediction of enhancers [62,206,207]. From these predictions a distinctive chro-
matin signature for promoters and enhancers was derived based on H3K4me1 and H3K4me3 [62].
In particular, the ratio H3K4me1/H3K4me3 was found to be low at promoters, in comparison
to enhancers. Active and poised enhancers could also be distinguished by presence or absence
of H3K27me3 and H3K9me3 [63]. All these features could be confirmed by GenoSTAN, making
it a promising tool for the biochemical characterization of enhancers and promoters. Moreover,
extensive benchmarks based on independent data including transcriptional activity, TF binding,
cis-regulatory activity, and enrichment for complex trait-associated variants showed the highest
accuracy of GenoSTAN annotations over former genome segmentation methods.
The GenoSTAN annotation sheds light on the common and distinctive features of promoters and
enhancers, which currently are an intense subject of debate [14,195]. Among other characteristics,
a shared architecture of promoters and enhancers was proposed based on the recent discovery of
widespread bidirectional transcription at enhancers [3, 13, 14]. This was supported by the obser-
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vation that enhancers, which are depleted in CpG islands have similar transcription factor (TF)
motif enrichments as CpG poor promoters [199]. However, another study showed that TF co-
occurrence differed between gene-proximal and gene-distal sites [180,215]. GenoSTAN chromatin
states revealed a very distinct TF regulatory landscape of these elements and therefore suggest
that promoters and enhancers are fundamentally different regulatory elements, both sharing the
binding of the core transcriptional machinery. Our annotation of enhancers and promoters will
be a valuable resource to help characterizing the genomic context of the binding of further TFs.
Indirectly, our analysis showed that chromatin state annotations are better predictors of en-
hancers than the transcription-based definition provided by the FANTOM5 consortium [199].
While FANTOM5 enhancers are an accurate predictor for transcriptionally active enhancers,
the sensitivity remains poor (only 4,263 enhancers were called by overlap with GRO-cap TSSs
and DHS, which is less than the estimated number of transcribed genes, for K562 cells com-
pared to about 20,000-30,000 for ChromHMM and 10,000-20,000 for GenoSTAN). Although, the
sensitivity of the transcription-based approach can increase with transient transcriptome profil-
ing [86, 218] or nascent transcriptome profiling [219], the chromatin state data undoubtedly add
valuable information for the identification of promoters and enhancers. Because it models count
data, GenoSTAN analysis can in principle also integrate RNA-seq profiles, for instance using it
in a strand-specific fashion [113].
Systematic identification of cis-regulatory active elements by direct activity assays is notoriously
difficult. STARR-Seq for instance is a high-throughput reporter assay for the de novo iden-
tification of enhancers [194]. It was previously used to identify thousands of cell-type specific
enhancers in Drosophila, but has not been applied to human yet. Moreover, STARR-Seq makes
rigid assumptions about the location of the enhancer element with respect to the promoter, and it
does not account for the native chromatin structure. This might identify regions that are inactive
in situ [194]. Other experimental assays for the validation of predicted ENCODE enhancers lead
to different results [192, 193]. Complementary to these approaches, the systematic evaluation of
cis-regulatory activity based on candidate regions in human cells have made progress with the
advent of high-throughput CRISPR perturbation assays [220]. Because it requires candidate cis-
regulatory regions in a first place, such approach will benefit from improved annotation maps as
the one we are providing.
Thus, we foresee GenoSTAN to be instrumental in future efforts to generate robust, genome-wide
maps of functional genomic regions like promoters and enhancers.
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16 TT-Seq captures the human transient transcriptome
All results presented in this section were obtained in collaboration with Margaux Michel and Björn
Schwalb and are part of the manuscript “TT-Seq captures the human transient transcriptome”,
which was accepted for publication in Science. For detailed author contributions see page ix.
Pervasive transcription at cis-regulatory elements generates many different RNA species in-
cluding protein-coding mRNAs and non-coding RNAs (ncRNAs), such as enhancer RNAs (eR-
NAs) [13,199,221]. Most ncRNAs are rapidly degraded and therefore difficult to detect. Sensitive
protocols to detect these short-lived RNAs such as GRO-cap [13] are limited to detection of the
transcription start sites. However, a comprehensive map of these transient RNAs in their full
length is required to understand regulation of RNA transcription and degradation.
To this end, transient transcriptome sequencing (TT-Seq) was developed, which maps transcribed
genomic regions with high sensitivity and enables the computation of RNA synthesis and degra-
dation rates with kinetic modeling (Appendix section 18 for details). The TT-Seq protocol is
a modfication of 4sU-Seq [222], where newly synthesized RNAs are labeled with the nucleoside
analog 4-thiouridine (4sU), which is incorporated into RNA during transcription. The labeled
RNAs are then purified and sequenced (Appendix Figure A10A, left panel). 4sU-Seq is more
sensitivity in detecting short lived RNAs than standard RNA-Seq [222]. However, the extracted
RNA in 4sU-Seq contains unlabeled 5’ parts, which were synthesized before 4sU labeling leading
to a 5’ bias of in the sequenced fragments (Appendix Figure A10B). TT-Seq modifies the 4sU-Seq
protocol by fragmenting the RNAs prior to isolation of labeled RNA (Appendix Figure A10A,
right panel). Thus only the labeled parts of newly synthesized RNA are extracted. This results
in an almost uniform coverage of sequenced RNA fragments (Appendix Figure A10B). Moreover,
kinetic modeling with TT-Seq allows quantification of RNA synthesis and degradation rates (see
Appendix section 18).
Here we apply GenoSTAN (see section 8 and 15) with TT-Seq in human K562 cells to generate
a comprehensive and sensitive map of the transcriptome, including thousands of transient RNAs
such as eRNAs. This map reveals differences between promoter and enhancer transcritption.
Moreover, we show that RNA sequence features correlate with degradation rates and transcript
lengths. Altogether, we anticipate the transcriptomic map derived using TT-Seq and GenoSTAN
to be a useful resource for studying transcription in human.
16.1 A comprehensive map of the transcriptome in human K562 cells
Using TT-Seq data we identified 21,874 genomic intervals of apparently uninterrupted tran-
scription (Transcriptional Units, TUs) by applying GenoSTAN with Poisson-lognormal emission
distributions (Figure 19A, Methods section 13). TT-Seq shows high sensitivity, recovering 65%
of the transcription start sites (TSSs) obtained by GRO-cap (overlapping segments in a window
of ± 400 bp) [13]. A total of 8,543 TUs overlapped a GENCODE annotation [104] in sense
direction of transcription (50% reciprocal overlap of segment size, Figure 5, Methods section 13),
revealing 7,810 mRNAs, 302 long intergenic non-coding RNAs (lincRNAs), and 431 antisense
RNAs (asRNA). 2,916 TUs overlapped with GENCODE annotations by less than 50% segment
size and were not classified. The remaining 10,415 (48%) TUs were newly detected ncRNAs that
we characterized further.
The remaining 10,415 non-annotated TUs were now classified based on the GenoSTAN-Poilog-
K562 (Figure 14, see section 15) chromatin state annotation and their positions relative to known
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Figure 19: Annotation of transient RNAs mapped by TT-Seq. (A) Genome browser view of an exemplary
region on chromosome 18. The depicted region shows transcripts from five of a total of seven transcript
classes. It also shows three of a total of 18 chromatin states (GenoSTAN-Poilog-K562, see section 15).
(B) Schematic giving the definition of transcript classes and color-code used for different RNA types. (C)
Number of transcripts in different classes (portions covered by GENCODE are hatched). (D) Distribution
of transcript lengths.
GENCODE annotations (Figure 19B). TUs within 1 kb of an GENCODE mRNA TSS included
685 upstream antisense RNAs (uaRNAs) [223] and 778 convergent RNAs (conRNAs) [224]. The
3,115 TUs on the strand opposite of a GENCODE mRNA were classified as antisense RNAs (as-
RNAs) when they were more than 1 kb away from the GENCODE mRNA TSS [225]. Remaining
TUs were grouped according to their underlying GenoSTAN-Poilog-K562 chromatin state at their
TSS. 2,580 TUs originate from promoter state regions (Methods section 13) and were called short
intergenic ncRNAs (sincRNAs) (Figure 19C). Most sincRNAs (67%) were located within 10 kb
of an GENCODE mRNA TSS. The remaining 3,257 TUs originate from enhancer state regions
(Methods section 13) and were classified as enhancer RNAs (eRNAs) [3, 226]. New ncRNAs are
short, and as sincRNAs are on average five times shorter than lincRNAs, and eRNAs have a
median length of only 974 nucleotides (Figure 19D).
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16.2 Transcript half-lives correlate with RNA sequence features
Kinetic modeling of TT-Seq and RNA-Seq data enabled us to estimate local RNA synthesis rates
(average nucleotide bond formation) and half-lives (average nucleotide bond breakage) genome-
wide (Appendix section 18) (Figure 20A, Appendix Figure A11A). We found that mRNAs and
lincRNAs have the highest synthesis rates and longest median half-lives, 50 min and 38 min, re-
spectively [218]. Other transcript classes show low synthesis and short mean half-lives, explaining
why these ncRNAs are generally not detected. Short RNA half-lives, as short as ∼ 2 minutes for
eRNAs, correlate with a lack of secondary structure [183] (Appendix Figure A11B). In eRNAs,
only 10% of the sequence is predicted to be structured, compared to 52% in mRNAs (Appendix
Figure A11C). Indeed the folding energy [183] of eRNAs compares to the genomic background
level (Figure 20B).
16.3 Differences in the transcription of promoters and enhancers
Our analysis further reveals differences in the transcription of promoters and enhancers [227].
With respect to initiation, enhancers show lower occupancy with the initiation factor TBP than
mRNA promoters (12-fold less, p-value < 10−16), whereas occupancies with factors involved in
polymerase pausing such as NELF-E and the P-TEFb subunit cyclin T2 [228] are similar (Figure
20C). eRNA synthesis terminates early (Figure 19D), likely because eRNAs are not enriched in
U1 snRNP-binding sites (U1 signals; GGUAAG, GUGAGU, or GGUGAG) that are known to
protect mRNA transcription from early termination [229, 230]. eRNAs contained U1 signals at
the level of genomic background (47%), whereas mRNAs were enriched (69%, p-value < 10−16)
(Figure 20D). Generally, an enrichment of U1 signals in the first 1,000 nucleotides positively
associated with RNA length for all transcript classes (Figure 20E). These results suggest that
evolution of stable RNAs generally involves acquisition of U1 signals, as shown previously for
uaRNAs [231].
16.4 Discussion
The use of genomic data or the interpretation of genetic variants highly depend on the reference
annotation of a genome. The transcriptome annotation using GenoSTAN with TT-Seq provides
an improved reference map of the human transcriptome in K562 cells. TT-Seq also allows the
calculation of RNA synthesis rates and half lives which we used with our annotation to derive
new insights into human genome transcription. This revealed differences between transcription of
promoters and enhancers. In particular, transcription factor binding differed between promoters
and enhancer and the of lack secondary structure correlated with short RNA half lives. The
occurence of U1 sites was found to be positively associated with transcript length, which were
present in enhancer RNAs at genomic background frequency but were enriched in mRNAs.
Differences and similarities between promoters and enhancers are currently under debate [14,195]
(see section 15.7 for a detailed discussion). Moreover, enhancer RNAs have been shown to
be required for proper enhancer function [232] or activition of the chromatin at the promoter
of the target gene [233], but the exact mechnisms of enhancer RNA function remain unclear.
Transcriptome mapping from TT-Seq data is a promosing tool for elucidating further features
and functions of transcripts from promoters and enhancers by providing higher sensitivity than
current RNA-Seq approaches to detect transient RNAs.
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Figure 20: Transcript half-lives correlate with RNA sequence features. (A) Distribution of half-lives in
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transcript classes. (E) Distribution of transcript lengths in transcript classes depends on the presence of
U1 signals in the first 1000 nt.
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Part IV
Conclusion
Recent technological advances (such as microarrays and Next-Generation-Sequencing) have made
it possible to measure genomic features and phenotypes in a genome-wide and cost-effective man-
ner. Consortia like ENCODE [93] and Roadmap Epigenomics [110] have generated today’s largest
data sets measuring a variety of genomic features (for instance histone modifications, transcrip-
tion factor binding, RNA expression, DNA accessibility or DNA methylation) in hundreds of cell
types and tissues. This huge amount of data requires new and efficient computational tools to
integrate, analyse and annotate these data. Accurate methods to accomplish this are therefore
crucial for current and future biological research.
In this thesis bidirectional HMMs (bdHMMs) were proposed for integration of strand-specific
with non-strand-specific data as well as a count-based HMM (GenoSTAN) for integration and
segmentation of sequencing data. Both methods are made available in the R/Bioconductor pack-
age STAN [113]. STAN provides a fast, multiprocessing implementation that can be run efficiently
on large genomes such as human.
The STAN package was used to infer accurate annotations of transcription in yeast (section 14)
and human K562 cells (section 16) and of cis-regulatory elements in 127 human cell types and
tissues (section 15). In particular, bdHMMs were used on a data set of yeast transcription factors
to annotate directed genomic states, each of which modeling a specific phase of the transcription
cycle. We found that the composition of protein factors in each state matched their known roles
in transcription and that the sequence of states in the transcription cycle is depenent on spe-
cific gene classes. Application to TT-Seq data in K562 cells provided a sensitive annotation of
the human transcriptome that also captured many transient RNAs. Analysis of this annotation
revealed differences in transcription of promoters and enhancers and the lack of U1 motifs and
RNA secondary structure as potential determinants of transcript length and stability. Prediction
of promoters and enhancers with STAN lead to an accurate map of cis-regulatory elements in
127 human cell types and tissues, revealing many biochemical and regulatory features that char-
acterize promoters and enhancers.
Taken together, we showed that STAN can be used to derive genome annotations, which are more
accurate than those of previous methods. Analysis of these improved annotations lead to new
biological insights. Thus the annotations derived in this thesis will be an important resource for
future genomic data analysis. Moreover, the broad applicability of STAN will make it possible
to infer such annotations also in other organisms and improve the current annotations as more
data becomes available.
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Appendix Figure A1: Median read coverage of GenoSTAN-nb-K562 chromatin states (left), their
number of annotated segments in the genome, their median width and distance to the closest GENCODE
TSS (middle). The right panel shows recall of genomic regions by chromatin states.
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Appendix Figure A2: (A) Heatmap of pairwise overlap (Jaccard index) of promoter (red) and enhancer
(orange) state annotations from different studies on benchmark I. Rows and columns were ordered by
separate clustering of promoter and enhancer overlaps. (B) Distribution of pairwise Jaccard indices for
strong promoters and enhancers (off-diagonal elements of promoter and enhancer sub-matrices from (A)).
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Appendix Figure A3: Comparison of GenoSTAN to other methods using 18 and 23 states on the
same data set in K562 (Benchmark I). (A-B) Performance of chromatin states in recovering GRO-cap
transcription start sites for the 18 and 23 state models. Cumulative FDR and recall are calculated by
subsequently adding states (sorted by decreasing precision). (C-D) The same as in (A-B) for ENCODE
HOT regions.
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Appendix Figure A4: Comparison of chromatin segmentation algorithms with respect to their ability
to call GRO-cap transcription start sites (left panels) and ENCODE HOT regions (right panels), as a
function of the state number used in the respective algorithm (x-axes). All models were learned on the data
set of benchmark I. (A-B) For each model, the state with highest precision in recalling HOT (respectively
TSS) regions is shown. (C-D) For each model, an area under curve (AUC) score (see Methods section 12)
is plotted to assess the spatial accuracy of a genome segmentation.
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Appendix Figure A5: GenoSTAN models for benchmark II. (A) Median read coverage of GenoSTAN-
Poilog-127 (Benchmark set II, fitted on the 127 ENCODE and Roadmap Epigenomics cell types and
tissues) chromatin states (left), their number of annotated segments in the genome, their median width
and distance to the closest GENCODE TSS of segments (middle). The right panel shows recall of genomic
regions by chromatin states. (B) The same as (A) for GenoSTAN-nb-127.
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Appendix Figure A6: GenoSTAN models for benchmark III. (A) Median read coverage of GenoSTAN-
Poilog-20 (Benchmark set III, fitted on the 20 ENCODE and Roadmap Epigenomics cell types and tissues)
chromatin states (left), their number of annotated segments in the genome, their median width and
distance to the closest GENCODE TSS of segments (middle). The right panel shows recall of genomic
regions by chromatin states. (B) The same as (A) for GenoSTAN-nb-20.
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Appendix Figure A7: Chromatin state annotations for benchmark II and III. GenoSTAN segmenta-
tions are shown with the three Roadmap Epigenomics ChromHMM segmentations with 15 (ChromHMM-
15), 18 (ChromHMM-18) and 25 (ChromHMM-25) states. Shown is the TAL1 locus with segmentations
and data from the K562 cell line.
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Appendix Figure A8: Enrichments of genetic variants associated with diverse traits in promoters are
specific to the relevant cell types. (A) The number of traits which are enriched in enhancer states in at least
one cell type or tissue is plotted for p-values < 0.05. (B) The same as in (A) but for promoters. (C) The
heatmap shows the -log10(p-value) of significantly enriched traits in promoter states (GenoSTAN-Poilog-
127, p-value < 0.05, marked by ’*’). P-values were adjusted for multiple testing using the Benjamin-
Hochberg correction.
84
N
u
m
b
e
r 
o
f 
e
n
h
a
n
ce
rs
N
u
m
b
e
r 
o
f 
e
n
h
a
n
ce
rs
N
u
m
b
e
r 
o
f 
p
ro
m
o
te
rs
N
u
m
b
e
r 
o
f 
p
ro
m
o
te
rs
Sample type Sample type
Tissue groupTissue group
A B
C D
E
S
−
d
e
ri
ve
d
B
ra
in
M
e
s
e
n
c
h
y
m
e
iP
S
C
D
ig
e
s
tiv
e
M
yo
s
ta
tin
M
u
s
c
le
IM
R
9
0
H
e
a
rt
S
m
o
o
th
 M
u
s
c
le
O
th
e
r
H
S
C
 &
 B
 c
e
ll
E
S
 c
e
ll
E
N
C
O
D
E
 2
0
1
2
A
d
ip
o
s
e
B
lo
o
d
 &
 T
 c
e
ll
E
p
ith
e
lia
l
N
e
u
ro
s
p
h
e
re
T
h
y
m
u
s
10000
20000
30000
40000
50000
N
e
u
ro
s
p
h
e
re
M
yo
s
ta
tin
S
m
o
o
th
 M
u
s
c
le
E
S
−
d
e
ri
ve
d
B
lo
o
d
 &
 T
 c
e
ll
B
ra
in
H
S
C
 &
 B
 c
e
ll
D
ig
e
s
tiv
e
iP
S
C
E
N
C
O
D
E
 2
0
1
2
E
S
 c
e
ll
O
th
e
r
M
u
s
c
le
M
e
s
e
n
c
h
y
m
e
IM
R
9
0
T
h
y
m
u
s
E
p
ith
e
lia
l
H
e
a
rt
A
d
ip
o
s
e
6000
8000
10000
12000
14000
16000
18000
E
S
 c
e
ll 
d
e
ri
ve
d
P
ri
m
a
ry
 c
e
lls
P
ri
m
a
ry
 T
is
s
u
e
P
ri
m
a
ry
 c
u
ltu
re
s
C
e
ll 
lin
e
6000
8000
10000
12000
14000
16000
18000
E
S
 c
e
ll 
d
e
ri
ve
d
P
ri
m
a
ry
 T
is
s
u
e
C
e
ll 
lin
e
P
ri
m
a
ry
 c
u
ltu
re
s
P
ri
m
a
ry
 c
e
lls
0
10000
20000
30000
40000
50000
Appendix Figure A9: Dependency of number of predicted promoters and enhancers on tissue group
and sample type. (A) Number of enhancer states per Roadmap Epigenomics cell/tissue group. (B) The
same as in (A) for promoters. (C) Number of enhancer states per Roadmap Epigenomics sample type.
(D) The same as in (C) for promoters.
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Benchmark I - K562 (one cell type)
Method/segmentation #promoters #enhancers
GenoSTAN-Poilog-K562 11,358 (Prom.11) 10,932 (Enh.15)
GenoSTAN-nb-K562 12,829 (Prom.22) 18,551 (Enh.6)
ChromHMM-Nature 16,118 (1_Active_Promoter) 30,492 (4_Strong_Enhancer)
ChromHMM-ENCODE 16,452 (Tss) 22,323 (Enh)
Segway-ENCODE 19,894 (Tss) 33,518 (Enh1)
Segway-nmeth 25,812 (8) 80,043 (0)
Segway-Reg.Build 13,668 (7_tss) 38,992 (11_proximal)
EpicSeg 16,192 (2) 53,982 (3)
Benchmark II & III - 127 cell types and tissues
Method/segmentation #promoters #enhancers
GenoSTAN-Poilog-127 15,229 (Prom.5) 45,955 (Enh.12)
GenoSTAN-nb-127 13,547 (Prom.19) 32,280 (Enh.6)
GenoSTAN-Poilog-20 12,710 (Prom.15) 19,730 (Enh.9)
GenoSTAN-nb-20 14,168 (Prom.14) 15,655 (Enh.9)
ChromHMM-15 21,002 (1_TssA) 92,824 (7_Enh)
ChromHMM-18 20,049 (1_TssA) 22,678 (9_EnhA1)
ChromHMM-25 12,525 (1_TssA) 12,706 (13_EnhA1)
Appendix Table A1: Number of promoter and enhancer states for the chromatin state annotations
analyzed in this study. The original state name is given in brackets.
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Benchmark I - K562 (one cell type)
Method/segmentation promoter states enhancer states
GenoSTAN-Poilog-K562 Prom.11, PromW.5 Enh.15, Enh.2
GenoSTAN-nb-K562 Prom.16, Prom.22 Enh.6, Enh.19
ChromHMM-ENCODE Tss, TssF Enh, EnhW
ChromHMM-nature
1_Active_Promoter 4_Strong_Enhancer,
2_Weak_Promoter 5_Strong_Enhancer
Segway-ENCODE Tss, PromF Enh1, Enh2
Segway-nmeth 8,6 0, 13
Segway-Reg.Build 7_tss, 0_proximal 1_proximal, 11_proximal
EpicSeg 2 3
Benchmark II & III - 127 cell types and tissues
Method/segmentation promoter states enhancer states
GenoSTAN-Poilog-127 Prom.19, Prom.5 Enh.12, EnhW.9
GenoSTAN-nb-127 Prom.1, Prom.19 Enh.6, EnhW.8
GenoSTAN-Poilog-20 Prom.15, Prom.6 Enh.9, EnhF.13
GenoSTAN-nb-20 Prom.14, Prom.21 Enh.9, EnhF.12
ChromHMM-15 1_TssA, 2_PromU 13_EnhA1, 14_EnhA2
ChromHMM-18 1_TssA, 2_TssFlnk 9_EnhA1, 10_EnhA2
ChromHMM-25 1_TssA, 2_TssAFlnk 7_Enh, 6_EnhG
Appendix Table A2: Table showing promoter and enhancer states used to calculate recall of FANTOM5
promoters and enhancers. Two promoter and enhancer states were used for each segmentation, except for
the EpicSeg segmentation, which only fitted one enhancer state.
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18 Additional information for section 16
All methods and analyses presented in Appendix Figure A10 and in sections 18.1 and 18.2 were
developed and performed by Margaux Michel and Björn Schwalb. They are included in this thesis
for the sake clarity and completeness. Results presented in Figure A11 were obtained in collabora-
tion with Margaux Michel and Björn Schwalb. These results are part of the manuscript “TT-Seq
captures the human transient transcriptome” which was accepted for publication in Science. For
detailed author contributions see page ix.
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Appendix Figure A10: TT-Seq enables nearly uniform mapping of the human transient transcriptome.
(A) Schematic representation of 4sU-Seq and TT-Seq methods (4sU, 4-thiouridine). (B) Metagene analysis
comparing TT-Seq to 4sU-Seq and RNA-Seq. Average coverage in 2,323 TUs (depleted for paused genes
as defined in [234]) is shown around the first TSS (left), the 5’-splice site (SS) of an intron of at least 10
kb (middle), and the last pA site (right) relative to the maximum in the first kb from the first TSS.
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18.1 Experimental protocol of transient trancriptome sequencing (TT-Seq)
K562 cells were acquired from DSMZ (Braunschweig, Germany). Cells were grown in RPMI
1640 medium (Gibco) supplemented with 10% heat-inactivated FBS (Gibco) and 1% Peni-
cillin/Streptomycin (100x, PAA) at 37°C under 5% CO2. Cells were labeled in media for 5
min with 500 μM 4-thiouridine (4sU, Sigma-Aldrich) and harvested through centrifugation for 2
min at 3,000 rpm. RNA extraction was performed with TRIzol (Life Technologies) following the
manufacturers’ instructions except for the addition of an RNA spike-in mix together with TRIzol.
The purified RNA was split in two samples and one of the two samples was fragmented at 240
ng/μl on a BioRuptor Next Gen (Diagenode) at high power for one cycle of 30”/30” ON/OFF.
Fragmented and non-fragmented samples were subjected to labeled RNA purification as previ-
ously described [85]. Labeled fragmented (TT-Seq), labeled (4sU-Seq), total (RNA-Seq) and total
fragmented (RNA-Seq with fragmentation) RNA were treated with 2 units of DNase Turbo (Life
Technologies) and sequencing libraries were prepared with the Ovation Human Blood RNA-Seq
library kit (NuGEN) following the manufacturers’ instructions. All samples were sequenced on
an Illumina HiSeq 1500 sequencer.
Six spike-ins (ERCC-00043, ERCC-00170, ERCC-00136, ERCC-00145, ERCC-00092 and ERCC-
00002) from the ERCC RNA spike-in mix (Life Technologies) were chosen as to have the same
nucleotide length and U numbers, but with different GC content (40 to 60%). Spike-ins were
amplified through PCR with the forward primer containing a T7 promoter sequence. Each
spike-in was subjected to in vitro transcription with the Megascript T7 Transcription Kit (Life
Technologies) with either 1:10 4sUTP:UTP ratio for spike-ins ERCC-00043, ERCC-00136 and
ERCC-00092 or only UTP for spike-ins ERCC-00170, ERCC-00145, ERCC-00002; resulting in
labeled and non-labeled spike-ins, respectively. All spike-ins were purified with AMPure XP
beads (Beckman-Coulter) and quantified with Nanodrop 2000 (Thermo Scientific), agarose gel
and Qubit 3.0 Fluorometer (Life Technologies). Spike-ins were then mixed in equal amount to a
final concentration of 6 ng/μl.
18.2 Estimation of RNA synthesis rates and half-lives
Estimation of RNA synthesis rates and half-lives. For all 19,219 classified TUs isoform-independent
exonic regions were determined using a model for constitutive exons [235]. Read counts for all
features were calculated using HTSeq [236]. To estimate rates of RNA synthesis and degradation,
we used a statistical model that describes the read counts kij for gene i in sample j (TT-Seq
or (total cellular) RNA-Seq samples) fragmented or total RNA-Seq samples) by gene-specific
amounts of labeled and unlabeled RNA amounts αi, βi. The model also includes a parameter Li
for the length of the respective feature, scaling factors σj that account for variations in sequencing
depth, and cross-contamination rate εj that models the proportion of unlabeled reads purified in
the TT-Seq sample. The expectation of the number of reads kij was modeled as:
E (kij) = Li · σj · (αi + εjβi)
Note that εj is set to 1 for the (total cellular) RNA samples. Sequencing depth σj and cross-
contamination rate εj were calculated using the spike-ins data, setting αi = 0 and βi = 1 for the
unlabeled spike-ins and setting αi = 1 and βi = 0 for the labeled spike-ins. The model was fitted
by maximum likelihood assuming negative binomial distribution with dispersion parameters as
calculated by DESeq2 [237]. Having sequencing depth σj and cross-contamination rate εj esti-
mated, the same model was applied to all TUs to provide estimates of the labeled and unlabeled
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RNA amounts αi, βi. These in turn were converted into synthesis and degradation rates (µi, λi)
assuming first-order kinetics as in [86] using the following equations:
αi =
µi
λi
·
(
1− e−λit
)
αi + βi =
µi
λi
where t = 5 minutes. And therefore:
λi (t) = −
1
t
log
(
βi
αi + βi
)
µi (t) = (αi + βi) · λi (t)
Note that this approach is customized for TT-Seq and introduces a conceptually new interpre-
tation of transcript stability because TT-Seq involves the fragmentation of labeled RNAs prior
to the purification of their labeled parts. Labeling and modeling approaches that were used so
far quantify RNAs as newly synthesized despite the fact that they carry a non-negligible part
of pre-existing RNA. This is introducing a bias especially towards longer genes given our short
labeling pulse of 5 minutes. Thus this approach can be applied to estimate the local synthesis
and degradation rates at any genomic position. When applied to a complete TU, it estimates the
typical synthesis rate and half-life of nucleotide bonds within the TU. We think this is necessary
given the complexity of the human genes with regard to the vast number of transcript isoforms
and the elaborate nature of splicing events that all influence the per gene estimation of synthesis
and decay. Note that TT-Seq data did not exhibit the so-called labeling bias.
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Appendix Figure A11: Transcript synthesis rates, half-lives, and predicted structure. (A) Distribution
of synthesis rates per transcript class. (B) Distribution of half lives of different transcript classes depending
on whether they are predicted to be structured or not (+, -). (C) Distribution of percentage of structured
RNA in different transcript classes.
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